Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Jan. 31, 2016	Apr. 15, 2016	Jul. 31, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	STREAMLINE HEALTH SOLUTIONS INC.
Entity Central Index Key	0001008586
Document Type	10-K
Document Period End Date	Jan. 31, 2016
Amendment Flag	false
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--01-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 45,488,878
Entity Common Stock, Shares Outstanding		19,361,549

Consolidated Balance Sheets - USD ($)	Jan. 31, 2016	Jan. 31, 2015
Current assets:
Cash and cash equivalents	$ 9,882,136	$ 6,522,600
Accounts receivable, net of allowance for doubtful accounts of $155,407 and $665,962, respectively	4,199,315	6,935,270
Contract receivables	119,697	191,465
Prepaid hardware and third party software for future delivery	5,858	55,173
Prepaid client maintenance contracts	956,913	935,858
Other prepaid assets	941,532	1,437,680
Deferred income taxes	0	220,004
Other current assets	97,986	207,673
Total current assets	16,203,437	16,505,723
Property and equipment:
Computer equipment	2,647,135	2,381,923
Computer software	801,895	964,857
Office furniture, fixtures and equipment	683,443	683,443
Leasehold improvements	729,348	724,015
Property and equipment, gross	4,861,821	4,754,238
Accumulated depreciation and amortization	(2,407,746)	(1,617,423)
Property and equipment, net	2,454,075	3,136,815
Contract receivables, less current portion	8,711	43,553
Capitalized software development costs, net of accumulated amortization of $14,919,948 and $11,846,468, respectively	6,123,638	9,197,118
Intangible assets, net	8,155,325	9,500,317
Deferred financing costs, net of accumulated amortization of $84,531 and $13,677, respectively	270,147	387,199
Goodwill	16,184,667	16,184,667
Other non-current assets	746,018	823,723
Total non-current assets	33,942,581	39,273,392
Total assets	50,146,018	55,779,115
Current liabilities:
Accounts payable	1,136,779	2,298,851
Accrued compensation	935,324	865,865
Accrued other expenses	328,551	563,838
Current portion of term loan	673,807	500,000
Deferred revenues	10,447,280	9,289,076
Current portion of capital lease obligation	592,642	781,961
Total current liabilities	14,114,383	14,299,591
Non-current liabilities:
Term loan	7,861,084	9,500,000
Warrants liability	205,113	1,834,380
Royalty liability	2,291,888	2,385,826
Lease incentive liability, less current portion	369,406	342,129
Capital lease obligation	93,257	582,911
Deferred revenues, less current portion	1,212,709	964,933
Deferred income tax liabilities	0	229,579
Total non-current liabilities	12,033,457	15,839,758
Total liabilities	26,147,840	30,139,349
Series A 0% Convertible Redeemable Preferred Stock, $.01 par value per share, $8,849,985 redemption and liquidation value, 4,000,000 shares authorized, 2,949,995 issued and outstanding, net of unamortized preferred stock discount of $875,935 and $2,212,007, respectively	7,974,050	6,637,978
Stockholders’ equity:
Common stock, $.01 par value per share, 45,000,000 shares authorized; 18,783,540 and 18,553,389 shares issued and outstanding, respectively	187,836	185,534
Additional paid in capital	79,700,577	78,390,424
Accumulated deficit	(63,864,285)	(59,574,170)
Total stockholders’ equity	16,024,128	19,001,788
Total liability and stockholders' equity	$ 50,146,018	$ 55,779,115

Consolidated Balance Sheets (Parenthetical) - USD ($)	12 Months Ended
Consolidated Balance Sheets (Parenthetical) - USD ($)	Jan. 31, 2016	Jan. 31, 2015
Allowance for doubtful accounts	$ 155,407	$ 665,962
Accumulated amortization of capitalized software development costs	14,919,948	11,846,468
Deferred financing costs, net of accumulated amortization of $84,531 and $13,677, respectively	$ 84,531	$ 13,677
Common stock, par value (USD per share)	$ 0.01	$ 0.01
Common stock, shares authorized	45,000,000	45,000,000
Common stock, shares issued	18,783,540	18,553,389
Common stock, shares outstanding	18,783,540	18,553,389
Series A Preferred Stock
Preferred stock dividend rate (as a percent)	0.00%	0.00%
Convertible redeemable preferred stock, par value (USD per share)	$ 0.01	$ 0.01
Convertible redeemable preferred stock, liquidation and redemption value	$ 8,849,985	$ 8,849,985
Convertible redeemable preferred stock, shares authorized	4,000,000	4,000,000
Convertible redeemable preferred stock, shares issued	2,949,995	2,949,995
Convertible redeemable preferred stock, shares outstanding	2,949,995	2,949,995
Unamortized preferred stock discount	$ 875,935	$ 2,212,007

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Jan. 31, 2016	Jan. 31, 2015
Revenues:
Systems sales	$ 2,946,304	$ 1,214,879
Professional services	2,212,002	2,580,167
Maintenance and support	15,145,480	16,157,371
Software as a service	8,010,672	7,672,990
Total revenues	28,314,458	27,625,407
Operating expenses:
Cost of systems sales	2,778,041	3,536,495
Cost of professional services	3,143,881	3,458,984
Cost of maintenance and support	3,036,550	3,087,842
Cost of software as a service	2,442,143	2,920,403
Selling, general and administrative	13,442,799	16,225,574
Research and development	9,093,353	9,756,206
Impairment of intangible assets	0	1,952,000
Total operating expenses	33,936,767	40,937,504
Operating loss	(5,622,309)	(13,312,097)
Other income (expense):
Interest expense	(884,226)	(748,969)
Loss on early extinguishment of debt	0	(429,849)
Miscellaneous income	2,224,423	1,592,449
Loss before income taxes	(4,282,112)	(12,898,466)
Income tax (expense) benefit	(8,003)	887,009
Net loss	(4,290,115)	(12,011,457)
Less: deemed dividends on Series A Preferred Shares	(1,336,072)	(1,038,310)
Net loss attributable to common shareholders	$ (5,626,187)	$ (13,049,767)
Basic net loss per common share (in dollars per share)	$ (0.30)	$ (0.71)
Number of shares used in basic per common share computation (shares)	18,689,854	18,261,800
Diluted net loss per common share (in dollars per share)	$ (0.30)	$ (0.71)
Number of shares used in diluted per common share computation (in shares)	18,689,854	18,261,800

Consolidated Statements of Comprehensive Loss - USD ($)	12 Months Ended
Consolidated Statements of Comprehensive Loss - USD ($)	Jan. 31, 2016	Jan. 31, 2015
Statement of Comprehensive Income [Abstract]
Net loss	$ (4,290,115)	$ (12,011,457)
Other comprehensive gain (loss), net of tax:
Fair value of interest rate swap liability	0	(3,436)
Reclassification adjustment for loss on settlement of interest rate swap liability realized in net loss	0	114,522
Other comprehensive income	0	111,086
Comprehensive loss	$ (4,290,115)	$ (11,900,371)

Consolidated Statements of Changes in Stockholders' Equity - USD ($)	Total	Common stock	Additional paid in capital	Accumulated deficit	Accumulated other comprehensive loss
Shares, beginning balance at Jan. 31, 2014		18,175,787
Stockholders' equity, beginning balance at Jan. 31, 2014	$ 29,491,047	$ 181,758	$ 76,983,088	$ (47,562,713)	$ (111,086)
Statement of Changes in stockholders' equity
Stock issued pursuant to Employee Stock Purchase Plan and exercise of stock options, shares		257,296
Stock issued pursuant to Employee Stock Purchase Plan and exercise of stock options	515,124	$ 2,573	512,551
Restricted stock issued, shares		120,306
Restricted stock issued	0	$ 1,203	(1,203)
Interest rate swap	111,086				111,086
Share-based compensation expense	1,934,298		1,934,298
Deemed dividends on Series A Preferred Stock	(1,038,310)		(1,038,310)
Net loss	(12,011,457)			(12,011,457)
Shares, ending balance at Jan. 31, 2015		18,553,389
Stockholders' equity, ending balance at Jan. 31, 2015	19,001,788	$ 185,534	78,390,424	(59,574,170)	0
Statement of Changes in stockholders' equity
Stock issued pursuant to Employee Stock Purchase Plan and exercise of stock options, shares		111,971
Stock issued pursuant to Employee Stock Purchase Plan and exercise of stock options	262,038	$ 1,120	260,918
Restricted stock issued, shares		118,180
Restricted stock issued		$ 1,182	(1,182)
Interest rate swap	0
Share-based compensation expense	2,386,489		2,386,489
Deemed dividends on Series A Preferred Stock	(1,336,072)		(1,336,072)
Net loss	(4,290,115)			(4,290,115)
Shares, ending balance at Jan. 31, 2016		18,783,540
Stockholders' equity, ending balance at Jan. 31, 2016	$ 16,024,128	$ 187,836	$ 79,700,577	$ (63,864,285)	$ 0

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Jan. 31, 2016	Jan. 31, 2015
Operating activities:
Net loss	$ (4,290,115)	$ (12,011,457)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities, net of effect of acquisitions:
Depreciation	1,245,400	1,005,283
Amortization of capitalized software development costs	3,073,479	3,677,991
Amortization of intangible assets	1,344,992	1,396,317
Amortization of other deferred costs	206,881	189,107
Amortization of debt discount	0	47,552
Valuation adjustment for warrants liability	(1,629,267)	(2,283,345)
Deferred tax expense (benefit)	(9,575)	(720,582)
Other valuation adjustments	(39,299)	128,855
Gain from early extinguishment of lease liability	(33,059)	0
Loss on impairment of intangible assets	0	1,952,000
Loss from early extinguishment of debt	0	315,327
Loss on disposal of fixed assets	92,448	180,793
Loss on exit of operating lease	0	234,823
Share-based compensation expense	2,386,490	1,934,298
Provision for accounts receivable	124,235	440,771
Changes in assets and liabilities, net of assets acquired:
Accounts and contract receivables	2,718,330	2,157,977
Other assets	575,774	(637,348)
Accounts payable	(1,117,986)	600,263
Accrued expenses	(174,133)	(1,422,571)
Deferred revenues	1,405,980	(197,698)
Net cash provided by (used in) operating activities	5,880,575	(3,011,644)
Investing activities:
Purchases of property and equipment	(518,254)	(2,125,240)
Capitalization of software development costs	0	(619,752)
Payment for acquisition, net of cash acquired	0	(6,058,225)
Net cash used in investing activities	(518,254)	(8,803,217)
Financing activities:
Proceeds from term loan	0	10,000,000
Principal repayments on term loans	(1,465,109)	(8,297,620)
Principal repayments on note payable	0	(900,000)
Principal payments on capital lease obligation	(815,826)	(368,386)
Recovery (payment) of deferred financing costs	2,111	(573,002)
Proceeds from exercise of stock options and stock purchase plan	276,039	551,583
Net cash (used in) provided by financing activities	(2,002,785)	412,575
Increase (decrease) in cash and cash equivalents	3,359,536	(11,402,286)
Cash and cash equivalents at beginning of year	6,522,600	17,924,886
Cash and cash equivalents at end of year	9,882,136	6,522,600
Supplemental cash flow disclosures:
Interest paid	917,212	518,919
Income taxes paid (received)	35,861	80,467
Supplemental disclosure of non-cash financing activities:
Deemed dividends on Series A Preferred Stock	$ 1,336,072	$ 1,038,310

Organization and Description of Business	12 Months Ended
Organization and Description of Business	Jan. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND DESCRIPTION OF BUSINESS	ORGANIZATION AND DESCRIPTION OF BUSINESS Streamline Health Solutions, Inc. and subsidiary (“we”, “us”, “our”, or the “Company”) operates in one segment as a provider of healthcare information technology through the licensing of its Electronic Health Information Management, Patient Financial Services, Coding and Clinical Documentation Improvement and other Workflow software applications and the use of such applications by software as a service. The Company also provides implementation and consulting services to complement its software solutions. The Company’s software and services enable hospitals and integrated healthcare delivery systems in the United States and Canada to capture, store, manage, route, retrieve, and process vast amounts of patient clinical, financial and other healthcare provider information. Fiscal Year All references to a fiscal year refer to the fiscal year commencing February 1 in that calendar year and ending on January 31 of the following year.

Significant Accounting Policies

12 Months Ended

Jan. 31, 2016

Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The consolidated financial statements include the accounts of Streamline Health Solutions, Inc. and its wholly-owned subsidiary, Streamline Health, Inc. All significant intercompany transactions are eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Cash and Cash Equivalents

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash demand deposits. Cash deposits are placed in Federal Deposit Insurance Corporation (“FDIC”) insured financial institutions. Cash deposits may exceed FDIC insured levels from time to time. For purposes of the Consolidated Balance Sheets and Consolidated Statements of Cash Flows, the Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.

Receivables

Accounts and contract receivables are comprised of amounts owed to the Company for licensed software, professional services, including maintenance services and software as a service and are presented net of the allowance for doubtful accounts. The timing of revenue recognition may not coincide with the billing terms of the client contract, resulting in unbilled receivables or deferred revenues; therefore certain contract receivables represent revenues recognized prior to client billings. Individual contract terms with clients or resellers determine when receivables are due. For billings where the criteria for revenue recognition have not been met, deferred revenue is recorded until all revenue recognition criteria have been met.

Allowance for Doubtful Accounts

In determining the allowance for doubtful accounts, aged receivables are analyzed monthly by management. Each identified receivable is reviewed based upon the most recent information available, including client comments, if any, and the status of any open or unresolved issues with the client preventing the payment thereof. Corrective action, if necessary, is taken by the Company to resolve open issues related to unpaid receivables. During these monthly reviews, the Company determines the required allowances for doubtful accounts for estimated losses resulting from the unwillingness or inability of its clients or resellers to make required payments. The allowance for doubtful accounts was approximately $155,000 and $666,000 at January 31, 2016 and 2015, respectively. The Company believes that its reserve is adequate, however results may differ in future periods.

Bad debt expense for fiscal years 2015 and 2014 was as follows:



	2015		2014
Bad debt expense	$	124,000	$	441,000

Concessions Accrual

In determining the concession accrual, the Company evaluates historical concessions granted relative to revenue. The concession accrual included in accrued other expenses on the Company's consolidated balance sheet was $54,000 and $58,000 as of January 31, 2016 and 2015, respectively.

Property and Equipment

Property and equipment are stated at cost. Depreciation is computed using the straight-line method, over the estimated useful lives of the related assets. Estimated useful lives are as follows:



Computer equipment and software	3-4 years
Office equipment	5 years
Office furniture and fixtures	7 years
Leasehold improvements	Term of lease

Depreciation expense for property and equipment in fiscal 2015 and 2014 was $1,245,000 and $1,005,000, respectively.

Normal repair and maintenance is expensed as incurred. Replacements are capitalized and the property and equipment accounts are relieved of the items being replaced or disposed of, if no longer of value. The related cost and accumulated depreciation of the disposed assets are eliminated and any gain or loss on disposition is included in the results of operations in the year of disposal.

Leases

On April 10, 2012, the Company entered into an amended lease obligation to lease 8,582 square feet of office space at 1230 Peachtree St. NE in Atlanta, Georgia. The lease commenced upon taking possession of the space and would have ended 72 months thereafter. The Company took possession of the space during the third quarter of fiscal 2012. Upon relocation, the Company completely vacated the previously leased premises within the same building. The provisions of the lease provided for rent abatement for the first four months of the lease term. Upon taking possession of the premises, the rent abatement was aggregated with the total expected rental payments, and was amortized on a straight-line basis over the term of the lease.

On December 13, 2013, the Company entered into an amended lease obligation to lease 24,335 square feet of office space in the same building as the office space in Atlanta, Georgia. The lease commenced upon taking possession of the space and ends 102 months thereafter. The Company took possession of the new space during the second quarter of fiscal 2014. Upon relocation, the Company completely vacated the previously leased premises within the building. The provisions of the lease provided for rent abatement for the first eight months of the lease term. Upon taking possession of the premises, the rent abatement and the unamortized balance of deferred rent associated with the previously leased premises were aggregated with the total expected rental payments, and are being amortized on a straight-line basis over the term of the new lease.

On August 16, 2012, as part of the acquisition of Meta Health Technology, the Company assumed a lease agreement for office space of approximately 10,000 square feet, at 330 Seventh Ave., New York, New York. This lease term expired on August 31, 2014. During the third quarter of fiscal 2014, the Company relocated its New York office to 105 Madison Avenue, New York, New York. The lease commenced upon taking possession of the space and ends 63 months thereafter. The provisions of the lease for the new office space of 10,350 square feet provided for rent abatement for the first two months of the lease term. Upon taking possession of the premises, the rent abatement was aggregated with the total expected rental payments, and is being amortized on a straight-line basis over the term of the lease.

The Company has capital leases to finance office equipment and maintenance services purchases. The balance of fixed assets acquired under these capital leases is $1,652,000 and $1,515,000 as of January 31, 2016 and 2015, respectively, and the balance of accumulated depreciation is $1,166,000 and $494,000 for the respective periods. The amortization expense of leased assets is included in depreciation expense.

Debt Issuance Costs

Costs related to the issuance of debt are capitalized and amortized to interest expense on a straight-line basis, which is not materially different from the effective interest method, over the term of the related debt.

Interest Rate Swap

In December 2013, the Company entered into an interest rate swap agreement to hedge against interest rate exposure of its variable rate debt obligation. The interest rate swap settled any accrued interest for cash on the first day of each calendar month until expiration. At such dates, the differences to be paid or received on the interest rate swaps was included in interest expense. The interest rate swap qualified for cash flow hedge accounting treatment and as such, the change in the fair values of the interest rate swap was recorded on the Company's consolidated balance sheet as an asset or liability with the effective portion of the interest rate swaps' gains or losses reported as a component of other comprehensive loss and the ineffective portion reported in net loss.

The fair value of the Company's interest rate swap was based on Level 2 inputs as described in ASC Topic 820, Fair Value Measurements and Disclosures, which include observable inputs such as dealer-quoted prices for similar assets or liabilities, and represented the estimated amount the Company would receive or pay to terminate the agreement taking into consideration various factors, including current interest rates, credit risk and counterparty credit risk.

During the third quarter of fiscal 2014, the interest rate swap was terminated prior to its maturity, and losses accumulated in other comprehensive loss were reclassified into earnings.

Impairment of Long-Lived Assets

The Company reviews the carrying value of long-lived assets whenever facts and circumstances exist that would suggest that assets might be impaired or that the useful lives should be modified. Among the factors the Company considers in making the evaluation are changes in market position and profitability. If facts and circumstances are present which may indicate impairment is probable, the Company will prepare a projection of the undiscounted cash flows of the specific asset and determine if the long-lived assets are recoverable based on these undiscounted cash flows. If impairment is indicated, an adjustment will be made to reduce the carrying amount of these assets to their fair value.

Capitalized Software Development Costs

Software development costs associated with the planning and designing phase of software development, including coding and testing activities necessary to establish technological feasibility, are classified as research and development and are expensed as incurred. Once technological feasibility has been determined, a portion of the costs incurred in development, including coding, testing, and quality assurance, are capitalized and subsequently reported at the lower of unamortized cost or net realizable value. The Company capitalized such costs, including interest, of $0 and $620,000 in fiscal 2015 and 2014, respectively. The Company acquired $2,017,000 of internally developed software in 2014 through the acquisition of Unibased, which is described in Note 3 - Acquisitions, and $3,646,000 through the acquisition of Meta in 2012.

Amortization for the Company's legacy software systems is provided on a solution-by-solution basis over the estimated economic life of the software, typically five years, using the straight-line method. Amortization commences when a solution is available for general release to clients. Acquired internally developed software from the Interpoint, Meta, and Unibased acquisitions is amortized using the straight-line method.

Amortization expense on all internally developed software was $3,073,000 and $3,678,000 in fiscal 2015 and 2014, respectively, and was included in the consolidated statements of operations as follows:



	Fiscal Year
Amortization expense on internally developed software included in:	2015		2014
Cost of systems sales	$	2,747,000	$	3,352,000
Cost of software as a service	326,000		326,000
Total amortization expense on internally developed software	$	3,073,000	$	3,678,000

Research and development expense, net of capitalized amounts, was $9,093,000 and $9,756,000 in fiscal 2015 and 2014, respectively.

Fair Value of Financial Instruments

The FASB’s authoritative guidance on fair value measurements establishes a framework for measuring fair value, and expands disclosure about fair value measurements. This guidance enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. Under this guidance, assets and liabilities carried at fair value must be classified and disclosed in one of the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value based on the short-term maturity of these instruments. Cash and cash equivalents are classified as Level 1. The carrying amount of the Company’s long-term debt approximates fair value since the variable interest rates being paid on the amounts approximate the market interest rate. Long-term debt is classified as Level 2.

The table below provides information on our liabilities that are measured at fair value on a recurring basis:



	Total Fair Value		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
At January 31, 2016
Warrants liability (1)	$	205,000	$	—	$	—	$	205,000
Royalty liability (2)	2,292,000		—		—		2,292,000

At January 31, 2015
Warrants liability (3)	$	1,834,000	$	—	$	—	$	1,834,000
Royalty liability (2)	2,386,000		—		—		2,386,000

_______________

(1)

The initial fair value of warrants liability was determined by management with the assistance of an independent third-party valuation specialist, and by management thereafter. See Note 4 - Derivative Liabilities, and Note 14 - Private Placement Investment for further details. Changes in fair value of the warrants are recognized within miscellaneous income in the consolidated statements of operations.

(2)

The initial fair value of royalty liability was determined by management with the assistance of an independent third-party valuation specialist, and by management thereafter. The fair value of the royalty liability is determined based on the probability-weighted revenue scenarios for the Looking Glass® Clinical Analytics solution licensed from Montefiore Medical Center (discussed in Note 3 - Acquisitions). Fair value adjustments are included within miscellaneous income in the consolidated statements of operations.


(3)	The fair value of warrants liability as of January 31, 2015 was determined by management with the assistance of an independent third-party valuation specialist using Monte-Carlo simulations. See Note 4 - Derivative Liabilities for further details.

Revenue Recognition

The Company derives revenue from the sale of internally developed software either by licensing or by software as a service (SaaS), through the direct sales force or through third-party resellers. Licensed, locally-installed, clients utilize the Company’s support and maintenance services for a separate fee, whereas SaaS fees include support and maintenance. The Company also derives revenue from professional services that support the implementation, configuration, training, and optimization of the applications. Additional revenues are also derived from reselling third-party software and hardware components.

The Company recognizes revenue in accordance with ASC 985-605, Software-Revenue Recognition and ASC 605-25 Revenue Recognition — Multiple-Element Arrangements. The Company commences revenue recognition when the following criteria all have been met:


•	Persuasive evidence of an arrangement exists,


•	Delivery has occurred or services have been rendered,


•	The arrangement fees are fixed or determinable, and


•	Collection is considered probable.

If we determine that any of the above criteria have not been met, we will defer recognition of the revenue until all the criteria have been met. Maintenance and support and SaaS agreements entered into are generally non-cancelable, or contain significant penalties for early cancellation, although clients typically have the right to terminate their contracts for cause if the Company fails to perform material obligations. However, if non-standard acceptance periods or non-standard performance criteria, cancellation or right of refund terms are required, revenue is recognized upon the satisfaction of such criteria, as applicable.

Multiple Element Arrangements

The Company applies the provisions of Accounting Standards Update No. 2009-13, Revenue Recognition (Topic 605), “Multiple-Deliverable Revenue Arrangements — a consensus of the FASB Emerging Issues Task Force” (“ASU 2009-13”). ASU 2009-13 amended the accounting standards for revenue recognition for multiple deliverable revenue arrangements to:


•	Provide updated guidance on how deliverables of an arrangement are separated, and how consideration is allocated;


•	Eliminate the residual method and require entities to allocate revenue using the relative selling price method and;


•	Require entities to allocate revenue to an arrangement using the estimated selling price (“ESP”) of deliverables if it does not have vendor specific objective evidence (“VSOE”) or third party evidence (“TPE”) of selling price.

Terms used in evaluation are as follows:


•	VSOE — the price at which an element is sold as a separate stand-alone transaction


•	TPE — the price of an element, charged by another company that is largely interchangeable in any particular transaction


•	ESP — the Company’s best estimate of the selling price of an element of the transaction

The Company follows accounting guidance for revenue recognition of multiple-element arrangements to determine whether such arrangements contain more than one unit of accounting. Multiple-element arrangements require the delivery or performance of multiple solutions, services and/or rights to use assets. To qualify as a separate unit of accounting, the delivered item must have value to the client on a stand-alone basis. Stand-alone value to a client is defined in the guidance as those that can be sold separately by any vendor or the client could resell the item on a stand-alone basis. Additionally, if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item or items must be considered probable and substantially in the control of the vendor.

The Company has a defined pricing methodology for all elements of the arrangement and proper review of pricing to ensure adherence to Company policies. Pricing decisions include cross-functional teams of senior management, which uses market conditions, expected contribution margin, size of the client’s organization, and pricing history for similar solutions when establishing the selling price.

Software as a Service

The Company uses ESP to determine the value for a software as a service arrangement as the Company cannot establish VSOE and TPE is not a practical alternative due to differences in functionality from the Company's competitors. Similar to proprietary license sales, pricing decisions rely on the relative size of the client purchasing the solution, and include calculating the equivalent value of maintenance and support on a present value basis over the term of the initial agreement period. Typically revenue recognition commences upon client go-live on the system, and is recognized ratably over the contract term.

Systems Sales

The Company uses the residual method to determine fair value for proprietary software licenses sold in a multi-element arrangement as the Company cannot establish fair value for all of the delivered elements. Typically pricing decisions for proprietary software rely on the relative size and complexity of the client purchasing the solution. Third-party components are resold at prices based on a cost plus margin analysis. The proprietary software and third-party components do not need any significant modification to achieve their intended use. When these revenues meet all the criteria for revenue recognition and are determined to be separate units of accounting, revenue is recognized. Typically, this is upon shipment of components or electronic download of software. Proprietary licenses are perpetual in nature, and license fees do not include rights to version upgrades, fixes or service packs.

Maintenance and Support Services

The maintenance and support components are not essential to the functionality of the software and clients renew maintenance contracts separately from software purchases at renewal rates materially similar to the initial rate charged for maintenance on the initial purchase of software. The Company uses VSOE of fair value to determine fair value of maintenance and support services. Generally, maintenance and support is calculated as a percentage of the list price of the proprietary license being purchased by a client. Clients have the option of purchasing additional annual maintenance service renewals each year for which rates are not materially different from the initial rate, but typically include a nominal rate increase based on the consumer price index. Annual maintenance and support agreements entitle clients to technology support, upgrades, bug fixes and service packs.

Term Licenses

We cannot establish VSOE of fair value of the undelivered element in term license arrangements. However, as the only undelivered element is post-contract customer support, the entire fee is recognized ratably over the contract term. Typically, revenue recognition commences once the client goes live on the system. Similar to proprietary license sales, pricing decisions rely on the relative size of the client purchasing the solution. The software portion of our coding and clinical documentation improvement solutions generally does not require material modification to achieve their contracted function.

Professional Services

Professional services components that are not essential to the functionality of the software, from time to time, are sold separately by the Company. Similar services are sold by other vendors, and clients can elect to perform similar services in-house. When professional services revenues are a separate unit of accounting, revenues are recognized as the services are performed based upon a proportional performance methodology.

Professional services components that are essential to the functionality of the software, and are not considered a separate unit of accounting, are recognized in revenue ratably over the life of the client, which approximates the duration of the initial contract term. The Company defers the associated direct costs for salaries and benefits expense for professional services contracts. These deferred costs will be amortized over the identical term as the associated SaaS revenues. As of January 31, 2016 and 2015, the Company had deferred costs of $571,000 and $570,000, respectively, net of accumulated amortization of $265,000 and $275,000, respectively. Amortization expense of these costs was $136,000 and $166,000 in fiscal 2015 and 2014, respectively.

The Company uses VSOE of fair value based on the hourly rate charged when services are sold separately, to determine fair value of professional services. The Company typically sells professional services on an hourly-fee basis. The Company monitors projects to assure that the expected and historical rate earned remains within a reasonable range to the established selling price.

Concentrations

Financial instruments, which potentially expose the Company to concentrations of credit risk, consist primarily of accounts receivable. The Company’s accounts receivable are concentrated in the healthcare industry. However, the Company’s clients typically are well-established hospitals, medical facilities, or major health information systems companies that resell the Company’s solutions that have good credit histories. Payments from clients have been received within normal time frames for the industry. However, some hospitals and medical facilities have experienced significant operating losses as a result of limits on third-party reimbursements from insurance companies and governmental entities and extended payment of receivables from these entities is not uncommon.

To date, the Company has relied on a limited number of clients and remarketing partners for a substantial portion of its total revenues. The Company expects that a significant portion of its future revenues will continue to be generated by a limited number of clients and its remarketing partners.

The Company currently buys all of its hardware and some major software components of its healthcare information systems from third-party vendors. Although there are a limited number of vendors capable of supplying these components, management believes that other suppliers could provide similar components on comparable terms.

Business Combinations

The assets acquired, liabilities assumed, and contingent consideration are recorded at their fair value on the acquisition date with subsequent changes recognized in earnings. These estimates are inherently uncertain and are subject to refinement. Management develops estimates based on assumptions as a part of the purchase price allocation process to value the assets acquired and liabilities assumed as of the business combination date. As a result, during the purchase price measurement period, which may be up to one year from the business combination date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. After the purchase price measurement period, the Company will record adjustments to assets acquired or liabilities assumed subsequent to the purchase price measurement period in operating expenses in the period in which the adjustments were determined.

The Company records acquisition and transaction related expenses in the period in which they are incurred. Acquisition and transaction related expenses primarily consist of legal, banking, accounting and other advisory fees of third parties related to potential acquisitions.

Goodwill and Intangible Assets

Goodwill and other intangible assets were recognized in conjunction with the Interpoint, Meta, CLG, and Unibased acquisitions. Identifiable intangible assets include purchased intangible assets with finite lives, which primarily consist of internally developed software, client relationships, supplier agreements, non-compete agreements, customer contracts, and license agreements. Finite-lived purchased intangible assets are amortized over their expected period of benefit, which generally ranges from one to 15 years, using the straight-line and undiscounted expected future cash flows methods. The indefinite-lived intangible asset related to the Meta trade name was not amortized, but was tested for impairment on at least an annual basis. In fiscal 2014, the Meta trade name was deemed impaired and its corresponding balance was fully written off (see Note 7 - Goodwill and Intangible Assets).

The Company assesses the useful lives and possible impairment of existing recognized goodwill and intangible assets when an event occurs that may trigger such a review. Factors considered important which could trigger a review include:


•	significant under performance relative to historical or projected future operating results;


•	significant changes in the manner of use of the acquired assets or the strategy for the overall business;


•	identification of other impaired assets within a reporting unit;


•	disposition of a significant portion of an operating segment;


•	significant negative industry or economic trends;


•	significant decline in the Company's stock price for a sustained period; and


•	a decline in the market capitalization relative to the net book value.

Determining whether a triggering event has occurred involves significant judgment by the Company.

The Company assesses goodwill annually (as of November 1), or more frequently when events and circumstances, such as the ones mentioned above, occur indicating that the recorded goodwill may be impaired. The Company did not note any of the above qualitative factors, which would be considered a triggering event for impairment. In assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company assesses relevant events and circumstances that may impact the fair value and the carrying amount of a reporting unit. The identification of relevant events and circumstances and how these may impact a reporting unit's fair value or carrying amount involve significant judgments by management. These judgments include the consideration of macroeconomic conditions, industry and market considerations, cost factors, overall financial performance, events which are specific to the Company, and trends in the market price of the Company's common stock. Each factor is assessed to determine whether it impacts the impairment test positively or negatively, and the magnitude of any such impact.

The two-step goodwill impairment test requires the Company to identify its reporting units and to determine estimates of the fair values of those reporting units as of the impairment testing date. Reporting units are determined based on the organizational structure the entity has in place at the date of the impairment test. A reporting unit is an operating segment or component business unit with the following characteristics: (a) it has discrete financial information, (b) segment management regularly reviews its operating results (generally an operating segment has a segment manager who is directly accountable to and maintains regular contact with the chief operating decision maker to discuss operating activities, financial results, forecasts, or plans for the segment), and (c) its economic characteristics are dissimilar from other units (this contemplates the nature of the products and services, the nature of the production process, the type or class of customer for the products and services, and the methods used to distribute the products and services).

The Company determined that it has one operating segment and one reporting unit.

To conduct a quantitative two-step goodwill impairment test, the fair value of the reporting unit is first compared to its carrying value. If the reporting unit's carrying value exceeds its fair value, the Company performs the second step and records an impairment loss to the extent that the carrying value of goodwill exceeds its implied fair value. The Company estimates the fair value of its reporting unit using a blend of market and income approaches. The market approach consists of two separate methods, including reference to the Company's market capitalization, as well as the guideline publicly traded company method. The market capitalization valuation method is based on an analysis of the Company's stock price on and around the testing date, plus a control premium. The guideline publicly traded company method was made by reference to a list of publicly traded software companies providing services to healthcare organizations, as determined by management. The market value of common equity for each comparable company was derived by multiplying the price per share on the testing date by the total common shares outstanding, plus a control premium. Selected valuation multiples are then determined and applied to appropriate financial statistics based on the Company's historical and forecasted results. The Company estimates the fair value of its reporting unit using the income approach, via discounted cash flow valuation models which include, but are not limited to, assumptions such as a “risk-free” rate of return on an investment, the weighted average cost of capital of a market participant, and future revenue, operating margin, working capital and capital expenditure trends. Determining the fair values of reporting units and goodwill includes significant judgment by management, and different judgments could yield different results.

The Company performed its annual assessment of goodwill during the fourth quarter of fiscal 2015, using the two-step approach described above. The first step of the goodwill impairment test, used to identify potential impairment, compares the fair value of a reporting unit with its carrying amount, including goodwill. Based on the analysis performed for step one, the fair value of the reporting unit exceeded the carrying amount of the reporting unit, including goodwill, and, therefore, an impairment loss was not recognized. As the Company passed step one of the analysis, step two was not required.

Severances

From time to time, we will enter into termination agreements with associates that may include supplemental cash payments, as well as contributions to health and other benefits for a specific time period subsequent to termination. In fiscal 2015 and 2014, we incurred $43,000 and $666,000 in severance expenses. At January 31, 2016 and 2015, we had accrued for $26,000 and $159,000 in severances, respectively.

Equity Awards

The Company accounts for share-based payments based on the grant-date fair value of the awards with compensation cost recognized as expense over the requisite vesting period. The Company incurred total annual compensation expense related to stock-based awards of $2,386,000 and $1,934,000 in fiscal 2015 and 2014, respectively.

The fair value of the stock options granted in fiscal 2015 and 2014 was estimated at the date of grant using a Black-Scholes option pricing model. Option pricing model input assumptions such as expected term, expected volatility, and risk-free interest rate impact the fair value estimate. Further, the forfeiture rate impacts the amount of aggregate compensation. These assumptions are subjective and are generally derived from external (such as, risk-free rate of interest) and historical data (such as, volatility factor, expected term, and forfeiture rates). Future grants of equity awards accounted for as stock-based compensation could have a material impact on reported expenses depending upon the number, value and vesting period of future awards.

The Company issues restricted stock awards in the form of Company common stock. The fair value of these awards is based on the market close price per share on the day of grant. The Company expenses the compensation cost of these awards as the restriction period lapses, which is typically a one-year service period to the Company.

Common Stock Warrants

As of January 31, 2016, the fair value of the common stock warrants was computed using the Black-Scholes option pricing model. The estimated fair value of the warrant liabilities as of January 31, 2015 was computed using Monte-Carlo simulations. Both valuations were based on assumptions regarding annual volatility, risk-free rate, dividend yield and expected life. The models also include assumptions to account for anti-dilutive provisions within the warrant agreement.

Other Comprehensive Income

Total other comprehensive income for fiscal years 2015 and 2014 was approximately zero and $111,000, respectively. Total other comprehensive income relates to the change in the unrealized loss on the Company's interest rate swap arrangement. The Company's interest rate swap arrangement is further described in Note 6 - Debt.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and for tax credit and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In assessing net deferred tax assets, the Company considers whether it is more likely than not that some or all of the deferred tax assets will not be realized. The Company establishes a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. See Note 8 - Income Taxes for further details.

The Company provides for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether certain tax positions are more likely than not to be sustained upon examination by tax authorities. At January 31, 2016, the Company believes it has appropriately accounted for any uncertain tax positions. As part of the Meta acquisition, the Company assumed a current liability for an uncertain tax position. The Company has recorded zero reserves for uncertain tax positions and corresponding interest and penalties as of both January 31, 2016 and January 31, 2015.

Net Loss Per Common Share

The Company presents basic and diluted earnings per share (“EPS”) data for its common stock. Basic EPS is calculated by dividing the net loss attributable to shareholders of the Company by the weighted average number of shares of common stock outstanding during the period. Diluted EPS is calculated based on the profit or loss attributable to shareholders and the weighted average number of shares of common stock outstanding adjusted for the effects of all potential dilutive common stock issuances related to options, unvested restricted stock, warrants and convertible preferred stock. Potential common stock dilution related to outstanding stock options, unvested restricted stock and warrants is determined using the treasury stock method, while potential common stock dilution related to Series A Convertible Preferred Stock is determined using the “if converted” method.

The Company's unvested restricted stock awards and Series A Convertible Preferred stock are considered participating securities under ASC 260, “Earnings Per Share” which means the security may participate in undistributed earnings with common stock. The Company's unvested restricted stock awards are considered participating securities because they entitle holders to non-forfeitable rights to dividends or dividend equivalents during the vesting term. The holders of the Series A Preferred Stock would be entitled to share in dividends, on an as-converted basis, if the holders of common stock were to receive dividends, other than dividends in the form of common stock. In accordance with ASC 260, a company is required to use the two-class method when computing EPS when a company has a security that qualifies as a “participating security.” The two-class method is an earnings allocation formula that determines EPS for each class of common stock and participating security according to dividends declared (or accumulated) and participation rights in undistributed earnings. In determining the amount of net earnings to allocate to common stock holders, earnings are allocated to both common and participating securities based on their respective weighted-average shares outstanding for the period. Diluted EPS for the Company's common stock is computed using the more dilutive of the two-class method or the if-converted method.

In accordance with ASC 260, securities are deemed to not be participating in losses if there is no obligation to fund such losses. For the years ended January 31, 2016 and 2015, the unvested restricted stock awards and the Series A Preferred Stock were deemed not to be participating since there was a net loss from operations for the years ended January 31, 2016 and 2015. As of both January 31, 2016 and 2015, there were 2,949,995 shares of preferred stock outstanding, each share is convertible into one share of the Company's common stock. For the years ended January 31, 2016 and 2015, the Series A Convertible Preferred Stock would have an anti-dilutive effect if included in Diluted EPS and, therefore, was not included in the calculation. As of January 31, 2016 and 2015, there were 112,380 and 120,306 unvested restricted shares of common stock outstanding, respectively. These unvested restricted shares were excluded from the calculation as their effect would have been antidilutive.

The following is the calculation of the basic and diluted net loss per share of common stock:



	Fiscal Year
	2015			2014
Net loss	$	(4,290,115	)	$	(12,011,457	)
Less: deemed dividends on Series A Preferred Stock	(1,336,072		)	(1,038,310		)
Net loss attributable to common shareholders	$	(5,626,187	)	$	(13,049,767	)
Weighted average shares outstanding used in basic per common share computations	18,689,854			18,261,800
Stock options and restricted stock	—			—
Number of average shares used in diluted per common share computation	18,689,854			18,261,800
Basic net loss per share of common stock	$	(0.30	)	$	(0.71	)
Diluted net loss per share of common stock	$	(0.30	)	$	(0.71	)

Diluted net loss per share excludes the effect of 2,411,879 and 2,437,323 outstanding stock options in fiscal 2015 and 2014, respectively. The inclusion of these shares would have been anti-dilutive. For fiscal 2015 and 2014, the outstanding common stock warrants of 1,400,000 would have an anti-dilutive effect if included in Diluted EPS and, therefore, were not included in the calculation.

Loss Contingencies

We are subject to the possibility of various loss contingencies arising in the course of business. We consider the likelihood of the loss or impairment of an asset or the incurrence of a liability as well as our ability to reasonably estimate the amount of loss in determining loss contingencies. An estimated loss contingency is accrued when it is probable that a liability has been incurred or an asset has been impaired and the amount of loss can be reasonably estimated. We regularly evaluate current information available to us to determine whether to accrue for a loss contingency and adjust any previous accrual.

Recent Accounting Pronouncements

In August 2014, the FASB issued an accounting standard update relating to disclosures of uncertainties about an entity’s ability to continue as a going concern. The update provides guidance about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures in the event that there is such substantial doubt. The update will be effective for us on February 1, 2017.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in ASC 605, Revenue Recognition. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In July 2015, the FASB delayed the effective date by one year and the guidance will now be effective for us on February 1, 2018. Early adoption is permitted. The guidance is to be applied using one of two retrospective application methods. We are currently evaluating the impact of the adoption of this accounting standard update on our internal processes, operating results, and financial reporting.

In April 2015, the FASB issued an accounting standard update relating to simplifying the presentation of debt issuance costs. The amendments in this update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The update will be effective for us on February 1, 2016.

In September 2015, the FASB issued an accounting standard update relating to the accounting for business combinations. The amendments in this update require that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The amendments in this update require that the acquirer record, in the same period’s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. The amendments in this update require an entity to present separately on the face of the income statement or disclose in the notes the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. The update will be effective for us on February 1, 2016.

In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes, to simplify the presentation of the deferred income taxes. The ASU requires that all deferred tax assets and liabilities, along with any related valuation allowance, be classified as noncurrent on the balance sheet. The guidance does not change the existing requirement that only permits offsetting within a tax-paying component of an entity. This guidance is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods, but may be adopted earlier. The Company elected to early adopt ASU 2015-17 prospectively in the fourth quarter of fiscal 2015. As a result, all deferred tax assets and liabilities will be presented as noncurrent on the consolidated balance sheet as of January 31, 2016. There was no impact on our results of operations as a result of the adoption of ASU 2015-17.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The ASU is effective for annual periods beginning after December 15, 2018, including interim periods within those fiscal years. The update will be effective for us on February 1, 2019. Early adoption of the update is permitted. The Company is evaluating the impact of the adoption of this update on our consolidated financial statements and related disclosures.

Acquisitions

12 Months Ended

Jan. 31, 2016

Business Combinations [Abstract]

ACQUISITIONS

On October 25, 2013, we entered into a Software License and Royalty Agreement (the “Royalty Agreement”) with Montefiore Medical Center (“Montefiore”) pursuant to which it entered into an agreement for an exclusive, worldwide 15-year license of Montefiore’s proprietary clinical analytics platform solution, Clinical Looking Glass® (“CLG”), now known as our Looking Glass® Clinical Analytics solution. In addition, Montefiore assigned to us the existing license agreement with a customer using CLG. As consideration under the Royalty Agreement, Streamline paid Montefiore a one-time initial base royalty fee of $3,000,000, and we are obligated to pay on-going quarterly royalty amounts related to future sublicensing of CLG by Streamline. Additionally, Streamline has committed that Montefiore will receive at least an additional $3,000,000 of on-going royalty payments within the first six and one-half years of the license term. As of January 31, 2016 and 2015, the present value of this royalty liability was $2,292,000 and $2,386,000, respectively.

On February 3, 2014, we completed the acquisition of Unibased Systems Architecture, Inc. (“Unibased”), a provider of patient access solutions, including enterprise scheduling and surgery management software, for healthcare organizations throughout the United States, pursuant to an Agreement and Plan of Merger dated January 16, 2014 (the “Merger Agreement”). The total purchase price for Unibased was $6,500,000, subject to net working capital and other customary adjustments. A portion of the total purchase price was withheld in escrow as described in the Merger Agreement for certain transaction and indemnification of claimed damages. In April 2015, the Company received $750,000 from the cash withheld in escrow, which is included in miscellaneous income.

Pursuant to the Merger Agreement, we acquired all of the issued and outstanding common stock of Unibased, and Unibased became a wholly-owned subsidiary of Streamline. Under the terms of the Merger Agreement, Unibased stockholders received cash for each share of Unibased common stock held. The preliminary purchase price was allocated to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date as follows:



	Balance at February 3, 2014
Assets purchased:
Cash	$	59,000
Accounts receivable	221,000
Other assets	61,000
Internally-developed software	2,017,000
Client relationships	647,000
Trade name	26,000
Goodwill (1)	4,251,000
Total assets purchased	7,282,000
Liabilities assumed:
Accounts payable and accrued liabilities	362,000
Deferred revenue obligation, net	793,000
Deferred income taxes	9,000
Net assets acquired	$	6,118,000
Cash paid	$	6,118,000

_______________


(1)	Goodwill represents the excess of purchase price over the estimated fair value of net tangible and intangible assets acquired, which is not deductible for tax purposes.

The operating results of Unibased are not material for proforma disclosure.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1524-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4922-128472

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4934-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4926-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=73530397&loc=SL65897772-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Derivative Liabilities	12 Months Ended
Derivative Liabilities	Jan. 31, 2016
Other Liabilities Disclosure [Abstract]
DERIVATIVE LIABILITIES	DERIVATIVE LIABILITIES As discussed further in Note 14 - Private Placement Investment, in conjunction with the 2012 private placement investment, the Company issued common stock warrants exercisable for up to 1,200,000 of common stock at an exercise price of $3.99 per share. The warrants were initially classified in stockholders' equity as additional paid-in capital at the allocated amount, net of allocated transaction costs, of $1,425,000. Effective October 31, 2012, upon stockholder approval of anti-dilution provisions that reset the warrant's exercise price if a dilutive issuance occurs, the warrants were reclassified as non-current derivative liabilities. The fair value of the warrants was $4,139,000 at October 31, 2012, with the difference between the fair value and carrying value recorded to additional paid-in capital. Effective as of the reclassification as derivative liabilities, the warrants are re-valued at each reporting date, with changes in fair value recognized in earnings each reporting period as a credit or charge to miscellaneous income (expense). The fair value of the warrants at January 31, 2016 and 2015 was $205,000 and $1,834,000, respectively. The change in fiscal 2015 and 2014 reflects $1,629,000 and $2,283,000, respectively, of miscellaneous income recognized in the consolidated statements of operations as a result of decreases in the fair value of the warrants. The estimated fair value of the warrant liabilities as of January 31, 2016 was computed using the Black-Scholes option pricing model based on the following assumptions: annual volatility of 60.1%; risk-free rate of 0.6%, dividend yield of 0.0% and expected life of two years. The estimated fair value of the warrant liabilities as of January 31, 2015 was computed using Monte-Carlo simulations based on the following assumptions: annual volatility of 55%; risk-free rate of 0.8%, dividend yield of 0.0% and expected life of three years.

Operating Leases

12 Months Ended

Jan. 31, 2016

Leases [Abstract]

OPERATING LEASES

The Company rents office and data center space and equipment under non-cancelable operating leases that expire at various times through fiscal year 2022. Future minimum lease payments under non-cancelable operating leases for the next five fiscal years and thereafter are as follows:



	Facilities		Equipment		Fiscal Year Totals
2016	$	969,000	$	2,000	$	971,000
2017	1,007,000		—		1,007,000
2018	1,039,000		—		1,039,000
2019	967,000		—		967,000
2020	504,000		—		504,000
Thereafter	964,000		—		964,000
Total	$	5,450,000	$	2,000	$	5,452,000

Rent and leasing expense for facilities and equipment was $1,274,000 and $1,652,000 for fiscal years 2015 and 2014, respectively.

Debt

12 Months Ended

Jan. 31, 2016

Debt Disclosure [Abstract]

DEBT

Term Loan and Line of Credit

In December 2013, we amended and restated our previously outstanding senior credit agreement and amended the subordinated credit agreement with Fifth Third Bank to increase the senior term loan to $8,500,000, reduce the interest rates, and extend the maturity of the senior term loan and the $5,000,000 revolving line of credit to December 1, 2018 and December 1, 2015, respectively. In January 2014, we paid the subordinated term loan in full. The outstanding senior term loan was secured by substantially all of our assets. The senior term loan principal balance was payable in monthly installments of $101,000, which started in January 2014 and would have continued through the maturity date, with the full remaining unpaid principal balance due at maturity. Borrowings under the senior term loan bore interest at a rate of LIBOR plus 5.25%. However, as a result of our interest rate swap, the interest rate was fixed at 6.42% until October 27, 2014, when the interest rate swap agreement was terminated. Accrued and unpaid interest on the senior term loan was due monthly through maturity. We paid $116,000 in closing fees in connection with this senior term loan, which was recorded as a debt discount and amortized to interest expense over the term of the loan using the effective interest method.

Borrowings under the revolving line of credit bore interest at a rate equal to LIBOR plus 3.50%. We paid a commitment fee of 0.40% on the unused revolving line of credit on a quarterly basis.

On November 21, 2014, we entered into a Credit Agreement (the “Credit Agreement”) with Wells Fargo Bank, N.A., as administrative agent, and other lender parties thereto. Pursuant to the Credit Agreement, the lenders agreed to provide a $10,000,000 senior term loan and a $5,000,000 revolving line of credit to our primary operating subsidiary. Amounts outstanding under the Credit Agreement bear interest at either LIBOR or the base rate, as elected by the Company, plus an applicable margin. Subject to the Company’s leverage ratio, the applicable LIBOR rate margin varies from 4.25% to 5.25%, and the applicable base rate margin varies from 3.25% to 4.25%. Pursuant to the terms of the amendment to the Credit Agreement entered into as of April 15, 2015, going forward the applicable LIBOR rate margin varies from 4.25% to 6.25%, and the applicable base rate margin varies from 3.25% to 5.25%. The term loan and line of credit mature on November 21, 2019 and provide support for working capital, capital expenditures and other general corporate purposes, including permitted acquisitions. At closing, the Company repaid indebtedness under its prior credit facility using approximately $7,400,000 of the proceeds provided by the term loan. The prior credit facility with Fifth Third Bank was terminated concurrent with the entry of the Credit Agreement and unamortized debt financing costs and discount of $315,000 associated with the terminated debt was included in loss on early extinguishment of debt. Financing costs of $355,000 associated with the new credit facility are being amortized over its term on a straight-line basis, which is not materially different from the effective interest method.

The Credit Agreement includes customary financial covenants, including the requirements that the Company maintain minimum liquidity and achieve certain minimum EBITDA levels (as defined in the Credit Agreement). In addition, the credit facility prohibits the Company from paying dividends on the common and preferred stock. In addition to the changes to the rate margins referenced above, the April 2015 amendment to the Credit Agreement reset the financial covenants. As such, the Company is required to maintain minimum liquidity of at least (i) $5,000,000 through April 15, 2015, (ii) $6,500,000 from April 16, 2015 through and including July 30, 2015, (iii) $7,000,000 from July 31, 2015 through and including January 30, 2016, and (iv) $7,500,000 from January 31, 2016 through and including the maturity date of the credit facility.

The following table shows our future minimum EBITDA covenant thresholds, as modified by the amendment to the Credit Agreement:



For the four-quarter period ended	Minimum EBITDA
April 30, 2015	$	(2,500,000	)
July 31, 2015	(1,750,000		)
October 31, 2015	(750,000		)
January 31, 2016	500,000

For the four-quarter period ending April 30, 2016, and fiscal quarters thereafter, the minimum EBITDA will be determined within 30 days following delivery of, and based upon, the projections then most recently delivered by the Company.

As of January 31, 2016, the Company had no outstanding borrowings under the revolving line of credit, and had accrued $2,000 in unused balance commitment fees.

Note Payable

In November 2013, as part of the settlement of the earn-out consideration in connection with the 2011 Interpoint acquisition, we issued an unsecured, subordinated three-year note in the amount of $900,000 (“Note Payable”) that would have matured on November 1, 2016 and accrued interest on the unpaid principal amount outstanding at a per annum rate equal to 8%. Annual principal payments of $300,000 were due on November 1, 2014, 2015 and 2016. At closing of the Credit Agreement with Wells Fargo described above, we repaid our indebtedness under this note using approximately $600,000 of the proceeds provided by the term loan.

Outstanding principal balances on debt consisted of the following at:



	January 31, 2016		January 31, 2015
Senior term loan	$	8,535,000	$	10,000,000
Capital lease	686,000		1,365,000
Total	9,221,000		11,365,000
Less: Current portion	1,266,000		1,282,000
Non-current portion of long-term debt	$	7,955,000	$	10,083,000

Future repayments of long-term debt by fiscal year consisted of the following at January 31, 2016:



	Senior Term Loan		Capital Lease (1)		Total
2016	$	674,000	$	618,000	$	1,292,000
2017	898,000		93,000		991,000
2018	898,000		—		898,000
2019	6,064,000		—		6,064,000
Total repayments	$	8,534,000	$	711,000	$	9,245,000

_______________


(1)	Future minimum lease payments include principal plus interest.

Interest Rate Swap

As of January 31, 2014, the Company maintained one effective hedging relationship via one distinct interest rate swap agreement (maturing December 1, 2020), which required the Company to pay interest at a fixed rate of 6.42% and receive interest at a variable rate. This interest rate swap agreement was designated to hedge $8,500,000 of a variable rate debt obligation. The one-month LIBOR rate on each reset date determined the variable portion of the interest rate swap for the following month. The interest rate swap settled any accrued interest for cash on the first day of each calendar month, until expiration. At such dates, the differences to be paid or received on the interest rate swap were included in interest expense. No premium or discount was incurred upon the Company entering into the interest rate swap, because the pay and receive rates on the interest rate swap represented prevailing rates for the counterparty at the time the interest rate swap was entered into.

The interest rate swap qualified for cash flow hedge accounting treatment and as such, the Company had effectively hedged its exposure to variability in the future cash flows attributable to the one-month LIBOR on its $8,500,000 of variable rate obligation. The change in the fair value of the interest rate swap was recorded on the Company’s consolidated balance sheet as an asset or liability with the effective portion of the interest rate swap’s gains or losses reported as a component of other comprehensive loss and the ineffective portion reported in earnings (interest expense). As of January 31, 2014, the Company had a fair value liability of approximately $111,000 for the effective portion of the interest rate swap. During the third quarter of fiscal 2014, the interest rate swap was terminated prior to its maturity, and losses accumulated in other comprehensive loss were reclassified into earnings.

Goodwill and Intangible Assets

12 Months Ended

Jan. 31, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND INTANGIBLE ASSETS

The goodwill activity is summarized as follows:



	Goodwill
Balance January 31, 2014	$	11,934,000
Goodwill acquired during fiscal 2014	4,251,000
Balance January 31, 2015 and January 31, 2016	$	16,185,000

Intangible assets, net, consist of the following:



	January 31, 2016
	Estimated Useful Life	Gross Assets		Accumulated Amortization		Net Assets
Definite-lived assets:
Trade name	1 year	$	26,000	$	26,000	$	—
Client relationships	10-15 years	5,932,000		2,220,000		3,712,000
Covenants not to compete	0.5-15 years	856,000		667,000		189,000
Supplier agreements	5 years	1,582,000		1,094,000		488,000
License agreement	15 years	4,431,000		665,000		3,766,000
Total		$	12,827,000	$	4,672,000	$	8,155,000



	January 31, 2015
	Estimated Useful Life	Gross Assets		Accumulated Amortization		Net Assets
Definite-lived assets:
Trade name	1 year	$	26,000	$	26,000	$	—
Client relationships	10-15 years	5,932,000		1,548,000		4,384,000
Covenants not to compete	0.5-15 years	856,000		606,000		250,000
Supplier agreements	5 years	1,582,000		778,000		804,000
License agreement	15 years	4,431,000		369,000		4,062,000
Total		$	12,827,000	$	3,327,000	$	9,500,000

In fiscal 2014, management determined that the concerted effort to rebrand the Company’s solutions under a single, harmonized Looking Glass® marketing platform moving forward, eroded, in total, the value of the Meta Trade name. As a result, the Company recorded a $1,952,000 loss, which is reflected in Impairment of intangible assets on the Consolidated Statements of Operations.

Amortization over the next five fiscal years for intangible assets is estimated as follows:



	Annual Amortization Expense
2016	$	1,298,000
2017	1,088,000
2018	863,000
2019	826,000
2020	791,000
Thereafter	3,289,000
Total	$	8,155,000

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Income Taxes

12 Months Ended

Jan. 31, 2016

Income Tax Disclosure [Abstract]

INCOME TAXES

Income taxes consist of the following:



	Fiscal Year
	2015			2014
Current tax (expense) benefit:
Federal	$	—		$	131,816
State	(17,578		)	34,611
	(17,578		)	166,427
Deferred tax benefit:
Federal	8,838			663,681
State	737			56,901
	9,575			720,582
Current and deferred tax (expense) benefit	$	(8,003	)	$	887,009

The income tax (expense) benefit for income taxes differs from the amount computed using the federal statutory income tax rate as follows:



	Fiscal Year
	2015			2014
Federal tax benefit at statutory rate	$	1,455,816		$	4,385,479
State and local taxes, net of federal benefit (expense)	(267,997		)	325,966
Change in valuation allowance	(1,629,786		)	(4,030,864		)
Permanent items:
Incentive stock options	(513,708		)	(421,366		)
Transaction costs	—			(5,291		)
Escrow refund	255,000			—
Change in fair value of warrants liability	553,951			776,337
Other	(28,914		)	(44,719		)
Reserve for uncertain tax position	—			164,127
Other	167,635			(262,660		)
Income tax (expense) benefit	$	(8,003	)	$	887,009

The Company provides deferred income taxes for temporary differences between assets and liabilities recognized for financial reporting and income tax purposes. The income tax effects of these temporary differences and credits are as follows:



	January 31,
	2016			2015
Deferred tax assets:
Allowance for doubtful accounts	$	58,379		$	245,252
Deferred revenue	244,163			372,275
Accruals	203,291			174,658
Net operating loss carryforwards	15,179,685			14,905,174
Stock compensation expense	592,654			438,659
Property and equipment	78,295			—
AMT credit	102,144			102,144
Other	17,794			8,912
Total deferred tax assets	16,476,405			16,247,074
Valuation allowance	(14,184,030		)	(12,554,242		)
Net deferred tax assets	2,292,375			3,692,832
Deferred tax liabilities:
Property and Equipment	—			(21,755		)
Definite-lived intangible assets	(2,292,375		)	(3,671,077		)
Indefinite-lived intangibles	—			(9,575		)
Total deferred tax liabilities	(2,292,375		)	(3,702,407		)
Net deferred tax liabilities	$	—		$	(9,575	)

At January 31, 2016, the Company had U.S. federal net operating loss carry forwards of $44,347,000, which expire at various dates through fiscal 2035. The Company also has an Alternative Minimum Tax net operating loss carry forward of $39,656,000, which has an unlimited carry forward period. The Company also had state net operating loss carry forwards of $16,144,000, which expire on or before fiscal 2035.

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. The Company established a valuation allowance of $14,184,000 and $12,554,000 at January 31, 2016 and 2015, respectively. The increase in the valuation allowance of $1,630,000 was driven primarily by losses incurred during the year ended January 31, 2016. Management believes it is more likely than not the Company will realize the remaining deferred tax assets, net of existing valuation allowances, in future years.

Due to the reporting requirements of ASC 718, $1,592,000 of the net operating loss carryforward (tax effected $588,000) is not recorded on the Company’s balance sheet because the loss was created by the tax benefits of stock option exercises, which cannot be recognized for book purposes until the benefit has been realized by actually reducing taxes payable. When recognized, the tax benefit of these losses will be accounted for as a credit to additional paid in capital rather than a reduction of the income tax provision.

The Company and its subsidiary are subject to U.S. federal income tax as well as income taxes in multiple state and local jurisdictions. The Company has concluded all U.S. federal tax matters for years through January 31, 2011. All material state and local income tax matters have been concluded for years through January 31, 2010.

The Company did not have a reserve for uncertain tax positions as of both January 31, 2016 and 2015. As of both January 31, 2016 and 2015, the Company had no accrued interest and penalties associated with unrecognized tax benefits.

A reconciliation of the beginning and ending amounts of gross unrecognized tax benefits (excluding interest and penalties) is as follows:



	2015		2014
Beginning of fiscal year	$	—	$	121,000
Additions for tax positions of prior years	—		—
Reductions for tax positions of prior years	—		—
Reductions attributable to lapse of statute of limitations	—		(121,000		)
End of fiscal year	$	—	$	—

Employee Retirement Plan	12 Months Ended
Employee Retirement Plan	Jan. 31, 2016
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]
EMPLOYEE RETIREMENT PLAN	EMPLOYEE RETIREMENT PLAN The Company has established a 401(k) retirement plan that covers all associates. Company contributions to the plan may be made at the discretion of the board of directors. The Company matches 100% up to the first 4% of compensation deferred by each associate in the 401(k) plan. The total compensation expense for this matching contribution was $499,000 and $440,000 in fiscal 2015 and 2014, respectively.

Employee Stock Purchase Plan	12 Months Ended
Employee Stock Purchase Plan	Jan. 31, 2016
Employee Stock Ownership Plan (ESOP), Shares in ESOP [Abstract]
EMPLOYEE STOCK PURCHASE PLAN	EMPLOYEE STOCK PURCHASE PLAN The Company has an Employee Stock Purchase Plan under which associates may purchase up to 1,000,000 shares of common stock. Under the plan, eligible associates may elect to contribute, through payroll deductions, up to 10% of their base pay to a trust during any plan year, i.e., January 1 through December 31 of the same year. Semi-annually, typically in January and July of each year, the plan issues for the benefit of the employees shares of common stock at the lesser of (a) 85% of the fair market value of the common stock on the first day of the vesting period, January 1 or July 1, or (b) 85% of the fair market value of the common stock on the last day of the vesting period, June 30 or December 31 of the same year. At January 31, 2016, 528,164 shares remain that can be purchased under the plan. The Company recognized compensation expense of $20,000 and $14,000 for fiscal years 2015 and 2014, respectively, under this plan. During fiscal 2015, 27,071 shares were purchased at the price of $2.38 per share and 42,050 shares were purchased at the price of $1.20 per share; during fiscal 2014, 11,141 shares were purchased at the price of $4.08 per share and 9,900 shares were purchased at the price of $3.68 per share. The cash received for shares purchased from the plan was $115,000 and $82,000 in fiscal 2015 and 2014, respectively. The purchase price at June 30, 2016, will be 85% of the lower of (a) the closing price on January 4, 2016 ($1.41) or (b) the closing price on June 30, 2016.

Stock Based Compensation

12 Months Ended

Jan. 31, 2016

Employee Stock Ownership Plan (ESOP), Shares in ESOP [Abstract]

STOCK BASED COMPENSATION

Stock Option Plans

The Company’s Amended and Restated 2013 Stock Incentive Plan (the “2013 Plan”) authorizes the Company to issue up to 4,500,000 equity awards (stock options, stock appreciation rights or “SAR’s”, and restricted stock) to directors and associates of the Company. The 2013 Plan replaced the 2005 Incentive Compensation Plan (the “2005 Plan”). Outstanding awards under the 2005 Plan continue to be governed by the terms of the 2005 Plan until exercised, expired or otherwise terminated or canceled, but no further equity awards are allowed to be granted under the 2005 Plan. The options granted under the 2013 Plan and 2005 Plan have terms of ten years or less, and typically vest and become fully exercisable ratably over three years of continuous service to the Company from the date of grant. At January 31, 2016 and 2015, options to purchase 2,186,879 and 1,737,323 shares of the Company’s common stock, respectively, have been granted and are outstanding. There are no SAR’s outstanding.

In fiscal 2015 and 2014, inducement grants were approved by the Company's Board of Directors pursuant to NASDAQ Marketplace Rule 5635(c)(4). The terms of the grants were nearly identical to the terms and conditions of the Company’s stock incentive plans in effect at the time of each inducement grant.

For the year ended January 31, 2016, no stock options were issued, 405,417 options expired, 69,583 options were forfeited, and no stock options were exercised. For the year ended January 31, 2015, 300,000 stock options were issued, 125,694 options expired, 99,722 were forfeited, and 205,556 were exercised. At January 31, 2016 and 2015, there were 225,000 and 700,000 options outstanding, respectively. Please see “Restricted Stock” section for information on the restricted shares.

A summary of stock option activity follows:



	Options		Weighted Average Exercise Price			Remaining Life in Years	Aggregate intrinsic value
Outstanding as of February 1, 2015	2,437,323		$	4.52
Granted	1,011,828		3.02
Exercised	(75,000	)	2.15
Expired	(704,326	)	3.67
Forfeited	(257,946	)	4.97
Outstanding as of January 31, 2016	2,411,879		$	4.16	(1)	8.09	$	4,003,719
Exercisable as of January 31, 2016	1,000,037		$	4.75	(2)	6.82	$	1,660,061
Vested or expected to vest as of January 31, 2016	1,990,872		$	4.25		7.90	$	3,304,848

_______________


(1)	The exercise prices range from $1.53 to $8.17, of which 207,924 shares are between $1.53 and $2.00 per share, 862,938 shares are between $2.08 and $4.00 per share, and 1,341,017 shares are between $4.02 and $8.17 per share.


(2)	The exercise prices range from $1.53 to $8.17, of which 97,924 shares are between $1.53 and $2.00 per share, 268,356 shares are between $2.08 and $4.00 per share, and 633,757 shares are between $4.02 and $8.17 per share.

For fiscal 2015 and 2014, the weighted average grant date fair value of options granted during the year was $1.64 and $2.90, respectively, and the total intrinsic value of options exercised during the year was $125,000 and $990,000, respectively.

The fiscal 2015 and 2014 stock-based compensation was estimated at the date of grant using a Black-Scholes option pricing model with the following weighted average assumptions for each fiscal year:



	2015		2014
Expected life	6 years		6 years
Risk-free interest rate	1.51	%	1.35	%
Weighted average volatility factor	0.59		0.60
Dividend yield	—		—
Forfeiture rate	30	%	22	%

At January 31, 2016, there was $1,588,000 of unrecognized compensation cost related to non-vested stock-option awards. That cost is expected to be recognized over a remaining weighted average period of 1.8 years. The expense associated with stock option awards was $1,783,000 and $1,655,000, respectively, for fiscal 2015 and 2014. Cash received from the exercise of options and purchases pursuant to the Employee Stock Purchase Plan was $276,000 and $552,000, respectively, in fiscal 2015 and 2014.

The 2005 Plan and the 2013 Plan contain change in control provisions whereby any outstanding equity awards under the plans subject to vesting, which have not fully vested as of the date of the change in control, shall automatically vest and become immediately exercisable. One of the change in control provisions is deemed to occur if there is a change in beneficial ownership, or authority to vote, directly or indirectly, securities representing 20% or more of the total of all of the Company’s then outstanding voting securities, unless through a transaction arranged by, or consummated with the prior approval of the Board of Directors. Other change in control provisions relate to mergers and acquisitions or a determination of change in control by the Company’s Board of Directors.

Restricted Stock

The Company is authorized to grant restricted stock awards to associates and directors under the 2013 Plan. The Company has also issued restricted stock as inducement grants to certain new employees. The restrictions on the shares granted generally lapse over a one-year term of continuous employment from the date of grant. The grant date fair value per share of restricted stock, which is based on the closing price of our common stock on the grant date, is expensed on a straight-line basis as the restriction period lapses. The shares represented by restricted stock awards are considered outstanding at the grant date, as the recipients are entitled to voting rights. A summary of restricted stock award activity for fiscal 2014 and 2015 is presented below:



	Non-vested Number of Shares		Weighted Average Grant Date Fair Value
Non-vested balance at January 31, 2014	29,698		$	6.01
Granted	120,306		4.31
Vested	(29,698	)	6.65
Forfeited/expired	—		—
Non-vested balance at January 31, 2015	120,306		$	4.31
Granted	118,180		2.62
Vested	(120,306	)	4.31
Forfeited/expired	(5,800	)	4.31
Non-vested balance at January 31, 2016	112,380		$	2.62

At January 31, 2016, there was $77,000 of unrecognized compensation cost related to restricted stock awards. That cost is expected to be recognized over a remaining period of one year or less.

The expense associated with restricted stock awards was $582,000 and $265,000, respectively, for fiscal 2015 and 2014.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Jan. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Litigation The Company is, from time to time, a party to various legal proceedings and claims, which arise in the ordinary course of business. Other than the matter described below, the Company is not aware of any legal matters that could have a material adverse effect on the Company’s consolidated results of operations, financial position, or cash flows. On February 12, 2014, the Company entered into a strategic alliance agreement with CentraMed, Inc. (“CentraMed”). On May 6, 2014, the Company signed an asset purchase agreement with CentraMed. This purchase agreement provided for the Company’s purchase of substantially all of CentraMed’s assets related to its business of providing healthcare analytics and consulting services to hospitals, physicians, and other providers. The agreement provided the Company the right to terminate the agreement in a number of circumstances, including if the Company was not satisfied, in its sole and absolute discretion, with the results of its due diligence review; the Company’s senior lender did not consent to the transactions contemplated by the agreement; or the Company’s Board did not authorize the transactions contemplated by the agreement. On January 12, 2015, the Company terminated the purchase agreement in accordance with its termination rights. On March 9, 2015, CentraMed asserted claims against the Company for breach of contract, misrepresentation, tortious interference with contracts and prospective economic relationships and bad faith in connection with the strategic alliance agreement and the asset purchase agreement. On March 24, 2015, the Company rejected the aforementioned claims and denied any liability to CentraMed. The Company intends to contest vigorously any action instituted against it by CentraMed. Because of the many questions of fact and law that may arise, the outcome of this matter is uncertain at this point. Based on the information available to us at present, we cannot reasonably estimate a range of loss for this matter and, accordingly, we have not accrued any liability associated with this matter.

Private Placement Investment

12 Months Ended

Jan. 31, 2016

Equity [Abstract]

PRIVATE PLACEMENT INVESTMENT

On August 16, 2012, the Company completed a $12,000,000 private placement investment (“private placement investment”) with affiliated funds and accounts of Great Point Partners, LLC, and Noro-Moseley Partners VI, L.P., and another investor. The investment consisted of the following instruments: issuance of 2,416,785 shares of a new Series A 0% Redeemable Convertible Preferred Stock (“Series A Preferred Stock”) at $3.00 per share, common stock warrants (“warrants”) exercisable for up to 1,200,000 shares of the Company's common stock at an exercise price of $3.99 per share, and convertible subordinated notes payable in the aggregate principal amount of $5,699,577, which upon stockholder approval, converted into 1,583,210 shares of Series A Preferred Stock. The proceeds were allocated among the instruments based on their relative fair values as follows:



	Adjusted Fair Value at August 16, 2012		Proceeds Allocation at August 16, 2012
Instruments:
Series A Preferred Stock	$	9,907,820	$	6,546,146	(1)
Convertible subordinated notes payable	5,699,577		3,765,738		(2)
Warrants	2,856,000		1,688,116		(3)
Total investment	$	18,463,397	$	12,000,000

_______________

(1)

The Series A Preferred Stock convert on a 1:1 basis into common stock, but differ in value from common stock due to the downside protection relative to common stock in the event the Company liquidates, and the downside protection, if, after four years, the holder has not converted and the stock is below $3.00. The fair value of Series A Preferred Stock was determined using a Monte-Carlo simulation following a Geometric Brownian Motion, using the following assumptions: annual volatility of 75%, risk-free rate of 0.9% and dividend yield of 0.0%. The model also utilized the following assumptions to account for the conditions within the agreement: after four years, if the simulated common stock price fell below a price of $3.00 per share, the convertible preferred stock would automatically convert to common stock on a 1:1 basis moving forward at a price of exactly $3.00 per share and a forced conversion if the simulated stock price exceeded $8.00 per share.

(2)

The fair value of convertible subordinated notes payable was determined based on its current yield as compared to that of those currently outstanding in the marketplace. Management reviewed the convertible note agreement and determined that the note's interest rate is a reasonable representative of a market rate; therefore the face or principal amount of the loan is a reasonable estimate of its fair value.

(3)

The fair value of the common stock warrants was determined using a Monte-Carlo simulation following a Geometric Brownian motion, using the following assumptions: annual volatility of 75%, risk-free rate of 0.9%, dividend yield of 0.0% and expected life of 5 years. Because the dilutive down-round financing was subject to stockholder approval, which had not happened at the time of the valuation, the model utilized the assumption that the down-round financing would not occur within the simulation.

The Company incurred legal, placement and other adviser fees of $1,894,000, including $754,000 in costs for warrants issued to placement agents. The total transaction costs were allocated among the instruments of the private placement investment based on their relative fair values as follows: $611,000 to subordinated convertible notes as deferred financing costs, $1,020,000 to Series A Preferred Stock as discount on Series A Preferred Stock and $263,000 to warrants as a charge to additional paid in capital.

Series A Convertible Preferred Stock

In connection with the private placement investment, the Company issued 2,416,785 shares of Series A Preferred Stock at $3.00 per share. Each share of the Series A Preferred Stock is convertible into one share of the Company's common stock. The price per share of Series A Preferred Stock and the conversion price for the common stock was less than the “market value” of the common stock of $3.82 (as defined in the rules of the Nasdaq Stock Market) on the date of execution of the definitive agreements. The Series A Preferred Stock does not pay a dividend, however, the holders are entitled to receive dividends on shares of Preferred Stock equal (on an as-if-converted-to-common-stock basis) to and in the same form as dividends (other than dividends in the form of common stock) actually paid on shares of the common stock. The Series A Preferred Stock has voting rights on a modified as-if-converted-to-common-stock-basis. The Series A Preferred Stock has a non-participating liquidation right equal to the original issue price plus accrued unpaid dividends, which are senior to the Company’s common stock. The Series A Preferred Stock can be converted to common shares at any time by the holders, or at the option of the Company if the arithmetic average of the daily volume weighted average price of the common stock for the ten day period prior to the measurement date is greater than $8.00 per share, and the average daily trading volume for the sixty day period immediately prior to the measurement date exceeds 100,000 shares. The conversion price is $3.00 per share, subject to certain adjustments.

The allocation of the proceeds and transaction costs based on relative fair values of the instruments resulted in recognition of a discount on the Series A Preferred Stock of $4,410,000, including a discount attributable to a beneficial conversion feature of $2,686,000, which is being amortized from the date of issuance to the earliest redemption date. For the years ended January 31, 2016 and 2015, the Company recognized $1,336,000 and $1,038,000, respectively, of amortization of the discount on Series A Preferred Stock as deemed dividends charged to additional paid in capital, computed under the effective interest rate method. The value of the beneficial conversion feature is calculated as the difference between the effective conversion price of the Series A Preferred Stock and the fair market value of the common stock into which the Series A Preferred Stock are convertible at the commitment date.

On November 1, 2012, upon shareholder approval, the convertible subordinated notes were converted into shares of Series A Convertible Preferred Stock. The convertible subordinated notes had an aggregate principal amount of $5,699,577 and converted into an aggregate of 1,583,210 shares of Preferred Stock. The Company recorded a loss upon conversion of $5,913,000, which represented the difference between the aggregate fair value of the Preferred Stock issued of $9,183,000, based on a $5.80 fair value per share, and the total of carrying value of the notes and unamortized deferred financing cost of $3,270,000. The shares of Series A Preferred Stock issued for the conversion of notes payable are recorded at their aggregate redemption value of $4,750,000 with the difference between the fair value and redemption value of $4,433,000 recorded as additional paid in capital. The fair value of the Preferred Stock was determined using a Monte-Carlo simulation based on the following assumptions: annual volatility of 75%, risk-free rate of 0.8%, and dividend yield of 0.0%. The model also utilized the following assumptions to account for the conditions within the agreement: after four years, if the simulated common stock price fell below a price of $3.00 per share, the convertible preferred stock would automatically convert to common stock on a 1:1 basis moving forward at a price of exactly $3.00 per share and a forced conversion if the simulated stock price exceeded $8.00 per share.

The following table sets forth the activity of the Series A Preferred Stock, classified as temporary equity, during the periods presented:



	Number of Shares	Series A Preferred Stock
Series A Preferred Stock, January 31, 2014	2,949,995	$	5,599,668
Accretion of Preferred Stock discount	—	1,038,310
Series A Preferred Stock, January 31, 2015	2,949,995	6,637,978
Accretion of Preferred Stock discount	—	1,336,072
Series A Preferred Stock, January 31, 2016	2,949,995	$	7,974,050

At any time following August 31, 2016, subject to the Subordination and Intercreditor among the preferred stockholders, the Company and Wells Fargo, each share of Series A Preferred Stock is redeemable at the option of the holder for an amount equal to the initial issuance price of $3.00 (adjusted to reflect stock splits, stock dividends or like events) plus any accrued and unpaid dividends thereon. The Series A Preferred Stock are classified as temporary equity as the securities are redeemable solely at the option of the holder.

In fiscal 2013, 1,050,000 shares of the Company's Series A Convertible Preferred Stock were converted into Common Stock. As a result, Series A Convertible Preferred Stock was reduced by $3,150,000, with the offsetting increase to Common Stock and Additional Paid-in Capital. As of January 31, 2016 and 2015, 2,949,995 shares of Series A Convertible Preferred Stock remained outstanding.

Common Stock Warrants

In conjunction with the private placement investment, the Company issued common stock warrants exercisable for up to 1,200,000 of the Company's common stock at an exercise price of $3.99 per share. The warrants can be exercised in whole or in part until February 16, 2018. The warrants also include a cashless exercise option which allows the holder to receive a number of shares of common stock based on an agreed upon formula in exchange for the warrant rather than paying cash to exercise. The proceeds, net of transaction costs, allocated to the warrants of $1,425,000 were classified as equity on August 16, 2012, the date of issuance.

Effective October 31, 2012, upon shareholder approval of anti-dilution provisions that reset the warrants’ exercise price if a dilutive issuance occurs, the warrants were reclassified as derivative liabilities. The provisions require the exercise price to reset to the lower price at which the dilutive issuance is consummated, if the dilutive issuance occurs prior to the second anniversary of the warrants’ issuance. If a dilutive issuance occurs after the second anniversary of the warrants’ issuance, then the exercise price will be reset in accordance with a weighted average formula that provides for a partial reset, based on the number of shares raised in the dilutive issuance relative to the number of common stock equivalents outstanding at the time of the dilutive issuance. The change in fair value of the warrants was accounted for as an adjustment to stockholders’ equity for the period between the date of the contract’s last classification as equity to the date of reclassification to liability. The fair value of the warrants was $4,139,000 at October 31, 2012. These warrants have been accounted for as derivative liabilities effective October 31, 2012, and as such, are re-valued at each reporting date, with changes in fair value recognized in earnings each reporting period as a charge or credit to other expenses.

On October 19, 2012, the Company also issued 200,000 warrants to its placement agents as a portion of the fees for services rendered in connection with the private placement investment. The warrants are exercisable through April 30, 2018 at a stated exercise price of $4.06 per share and can be exercised in whole or in part. The warrants also include a cashless exercise option that allows the holder to receive a number of shares of common stock based on an agreed upon formula in exchange for the warrants rather than paying cash to exercise. The warrants have no reset provisions. The warrants had a grant date fair value of $754,000, and are classified as equity on the consolidated balance sheet. The estimated fair value of the warrants was determined by using Monte-Carlo simulations based on the following assumptions: annual volatility of 75%; risk-free rate of 0.9%, dividend yield of 0.0% and expected life of five years.

The following table sets forth the warrants issued and outstanding as of January 31, 2016:



	Number of Shares Issuable	Weighted Average Exercise Price
Warrants - private placement	1,200,000	$	3.99
Warrants - placement agent	200,000	4.06
Total	1,400,000	$	4.00

The fair value of the private placement warrants was $205,000 and $1,834,000 at January 31, 2016 and 2015, respectively. No warrants were exercised or canceled during fiscal 2015 and 2014.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Schedule II - Valuation and Qualifying Accounts and Reserves

12 Months Ended

Jan. 31, 2016

Valuation and Qualifying Accounts [Abstract]

Schedule II - Valuation and Qualifying Accounts and Reserves

Schedule II

Valuation and Qualifying Accounts and Reserves

Streamline Health Solutions, Inc.

For the two years ended January 31, 2016



			Additions
Description	Balance at Beginning of Period		Charged to Costs and Expenses		Charged to Other Accounts		Deductions			Balance at End of Period
	(in thousands)
Year ended January 31, 2016:
Allowance for doubtful accounts	$	666	$	48	$	—	$	(559	)	$	155
Year ended January 31, 2015:
Allowance for doubtful accounts	$	267	$	441	$	1	$	(43	)	$	666

Significant Accounting Policies (Policies)

12 Months Ended

Jan. 31, 2016

Accounting Policies [Abstract]

Basis of Presentation

Use of Estimates

Cash and Cash Equivalents

Receivables and Allowance for Doubtful Accounts

Receivables

Allowance for Doubtful Accounts

Concessions Accrual

Property and Equipment

Property and equipment are stated at cost. Depreciation is computed using the straight-line method, over the estimated useful lives of the related assets. Estimated useful lives are as follows:



Computer equipment and software	3-4 years
Office equipment	5 years
Office furniture and fixtures	7 years
Leasehold improvements	Term of lease

Depreciation expense for property and equipment in fiscal 2015 and 2014 was $1,245,000 and $1,005,000, respectively.

Leases

Debt Issuance Costs

Interest Rate Swap

During the third quarter of fiscal 2014, the interest rate swap was terminated prior to its maturity, and losses accumulated in other comprehensive loss were reclassified into earnings.

Impairment of Long-Lived Assets

Capitalized Software Development Costs

Fair Value of Financial Instruments

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

Revenue Recognition


•	Persuasive evidence of an arrangement exists,


•	Delivery has occurred or services have been rendered,


•	The arrangement fees are fixed or determinable, and


•	Collection is considered probable.

Multiple Element Arrangements


•	Provide updated guidance on how deliverables of an arrangement are separated, and how consideration is allocated;


•	Eliminate the residual method and require entities to allocate revenue using the relative selling price method and;


•	Require entities to allocate revenue to an arrangement using the estimated selling price (“ESP”) of deliverables if it does not have vendor specific objective evidence (“VSOE”) or third party evidence (“TPE”) of selling price.

Terms used in evaluation are as follows:


•	VSOE — the price at which an element is sold as a separate stand-alone transaction


•	TPE — the price of an element, charged by another company that is largely interchangeable in any particular transaction


•	ESP — the Company’s best estimate of the selling price of an element of the transaction

Software as a Service

Systems Sales

Maintenance and Support Services

Term Licenses

Professional Services

Concentrations

Business Combinations

Goodwill and Intangible Assets


•	significant under performance relative to historical or projected future operating results;


•	significant changes in the manner of use of the acquired assets or the strategy for the overall business;


•	identification of other impaired assets within a reporting unit;


•	disposition of a significant portion of an operating segment;


•	significant negative industry or economic trends;


•	significant decline in the Company's stock price for a sustained period; and


•	a decline in the market capitalization relative to the net book value.

Determining whether a triggering event has occurred involves significant judgment by the Company.

The Company determined that it has one operating segment and one reporting unit.

Severances

Equity Awards

Common Stock Warrants

Other Comprehensive Income

Income Taxes

Net Loss Per Common Share

Loss Contingencies

Recent Accounting Pronouncements

Significant Accounting Policies (Tables)

12 Months Ended

Jan. 31, 2016

Accounting Policies [Abstract]

Schedule of Bad Debt Expense

Bad debt expense for fiscal years 2015 and 2014 was as follows:



	2015		2014
Bad debt expense	$	124,000	$	441,000

Property, Plant and Equipment

Property and equipment are stated at cost. Depreciation is computed using the straight-line method, over the estimated useful lives of the related assets. Estimated useful lives are as follows:



Computer equipment and software	3-4 years
Office equipment	5 years
Office furniture and fixtures	7 years
Leasehold improvements	Term of lease

Fair Value of Liabilities on a Recurring Basis

The table below provides information on our liabilities that are measured at fair value on a recurring basis:



	Total Fair Value		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
At January 31, 2016
Warrants liability (1)	$	205,000	$	—	$	—	$	205,000
Royalty liability (2)	2,292,000		—		—		2,292,000

At January 31, 2015
Warrants liability (3)	$	1,834,000	$	—	$	—	$	1,834,000
Royalty liability (2)	2,386,000		—		—		2,386,000

_______________

(1)

(2)


(3)	The fair value of warrants liability as of January 31, 2015 was determined by management with the assistance of an independent third-party valuation specialist using Monte-Carlo simulations. See Note 4 - Derivative Liabilities for further details.

Schedule of Capitalized Software Development Costs



	Fiscal Year
Amortization expense on internally developed software included in:	2015		2014
Cost of systems sales	$	2,747,000	$	3,352,000
Cost of software as a service	326,000		326,000
Total amortization expense on internally developed software	$	3,073,000	$	3,678,000

Schedule of Earnings Per Share, Basic and Diluted

The following is the calculation of the basic and diluted net loss per share of common stock:



	Fiscal Year
	2015			2014
Net loss	$	(4,290,115	)	$	(12,011,457	)
Less: deemed dividends on Series A Preferred Stock	(1,336,072		)	(1,038,310		)
Net loss attributable to common shareholders	$	(5,626,187	)	$	(13,049,767	)
Weighted average shares outstanding used in basic per common share computations	18,689,854			18,261,800
Stock options and restricted stock	—			—
Number of average shares used in diluted per common share computation	18,689,854			18,261,800
Basic net loss per share of common stock	$	(0.30	)	$	(0.71	)
Diluted net loss per share of common stock	$	(0.30	)	$	(0.71	)

Acquisitions (Tables)

12 Months Ended

Jan. 31, 2016

Business Combinations [Abstract]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The preliminary purchase price was allocated to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date as follows:



	Balance at February 3, 2014
Assets purchased:
Cash	$	59,000
Accounts receivable	221,000
Other assets	61,000
Internally-developed software	2,017,000
Client relationships	647,000
Trade name	26,000
Goodwill (1)	4,251,000
Total assets purchased	7,282,000
Liabilities assumed:
Accounts payable and accrued liabilities	362,000
Deferred revenue obligation, net	793,000
Deferred income taxes	9,000
Net assets acquired	$	6,118,000
Cash paid	$	6,118,000

_______________


(1)	Goodwill represents the excess of purchase price over the estimated fair value of net tangible and intangible assets acquired, which is not deductible for tax purposes.

Debt (Tables)

12 Months Ended

Jan. 31, 2016

Debt Disclosure [Abstract]

Schedule of Minimum EBITDA Levels

The following table shows our future minimum EBITDA covenant thresholds, as modified by the amendment to the Credit Agreement:



For the four-quarter period ended	Minimum EBITDA
April 30, 2015	$	(2,500,000	)
July 31, 2015	(1,750,000		)
October 31, 2015	(750,000		)
January 31, 2016	500,000

Summary of Term Loan and Line of Credit

Outstanding principal balances on debt consisted of the following at:



	January 31, 2016		January 31, 2015
Senior term loan	$	8,535,000	$	10,000,000
Capital lease	686,000		1,365,000
Total	9,221,000		11,365,000
Less: Current portion	1,266,000		1,282,000
Non-current portion of long-term debt	$	7,955,000	$	10,083,000

Schedule of Future Principal Repayments of Long-Term Debt

Future repayments of long-term debt by fiscal year consisted of the following at January 31, 2016:



	Senior Term Loan		Capital Lease (1)		Total
2016	$	674,000	$	618,000	$	1,292,000
2017	898,000		93,000		991,000
2018	898,000		—		898,000
2019	6,064,000		—		6,064,000
Total repayments	$	8,534,000	$	711,000	$	9,245,000

_______________


(1)	Future minimum lease payments include principal plus interest.

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

+ Details

Goodwill and Intangible Assets (Tables)

12 Months Ended

Jan. 31, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill Activity

The goodwill activity is summarized as follows:



	Goodwill
Balance January 31, 2014	$	11,934,000
Goodwill acquired during fiscal 2014	4,251,000
Balance January 31, 2015 and January 31, 2016	$	16,185,000

Schedule of Intangible Asset Components

Intangible assets, net, consist of the following:



	January 31, 2016
	Estimated Useful Life	Gross Assets		Accumulated Amortization		Net Assets
Definite-lived assets:
Trade name	1 year	$	26,000	$	26,000	$	—
Client relationships	10-15 years	5,932,000		2,220,000		3,712,000
Covenants not to compete	0.5-15 years	856,000		667,000		189,000
Supplier agreements	5 years	1,582,000		1,094,000		488,000
License agreement	15 years	4,431,000		665,000		3,766,000
Total		$	12,827,000	$	4,672,000	$	8,155,000



	January 31, 2015
	Estimated Useful Life	Gross Assets		Accumulated Amortization		Net Assets
Definite-lived assets:
Trade name	1 year	$	26,000	$	26,000	$	—
Client relationships	10-15 years	5,932,000		1,548,000		4,384,000
Covenants not to compete	0.5-15 years	856,000		606,000		250,000
Supplier agreements	5 years	1,582,000		778,000		804,000
License agreement	15 years	4,431,000		369,000		4,062,000
Total		$	12,827,000	$	3,327,000	$	9,500,000

Amortization Schedule of Intangible Assets

Amortization over the next five fiscal years for intangible assets is estimated as follows:



	Annual Amortization Expense
2016	$	1,298,000
2017	1,088,000
2018	863,000
2019	826,000
2020	791,000
Thereafter	3,289,000
Total	$	8,155,000

Income Taxes (Tables)

12 Months Ended

Jan. 31, 2016

Income Tax Disclosure [Abstract]

Schedule of Components of Income Tax Expense (Benefit)

Income taxes consist of the following:



	Fiscal Year
	2015			2014
Current tax (expense) benefit:
Federal	$	—		$	131,816
State	(17,578		)	34,611
	(17,578		)	166,427
Deferred tax benefit:
Federal	8,838			663,681
State	737			56,901
	9,575			720,582
Current and deferred tax (expense) benefit	$	(8,003	)	$	887,009

Schedule of Effective Income Tax Rate Reconciliation

The income tax (expense) benefit for income taxes differs from the amount computed using the federal statutory income tax rate as follows:



	Fiscal Year
	2015			2014
Federal tax benefit at statutory rate	$	1,455,816		$	4,385,479
State and local taxes, net of federal benefit (expense)	(267,997		)	325,966
Change in valuation allowance	(1,629,786		)	(4,030,864		)
Permanent items:
Incentive stock options	(513,708		)	(421,366		)
Transaction costs	—			(5,291		)
Escrow refund	255,000			—
Change in fair value of warrants liability	553,951			776,337
Other	(28,914		)	(44,719		)
Reserve for uncertain tax position	—			164,127
Other	167,635			(262,660		)
Income tax (expense) benefit	$	(8,003	)	$	887,009

Schedule of Deferred Tax Assets and Liabilities

The income tax effects of these temporary differences and credits are as follows:



	January 31,
	2016			2015
Deferred tax assets:
Allowance for doubtful accounts	$	58,379		$	245,252
Deferred revenue	244,163			372,275
Accruals	203,291			174,658
Net operating loss carryforwards	15,179,685			14,905,174
Stock compensation expense	592,654			438,659
Property and equipment	78,295			—
AMT credit	102,144			102,144
Other	17,794			8,912
Total deferred tax assets	16,476,405			16,247,074
Valuation allowance	(14,184,030		)	(12,554,242		)
Net deferred tax assets	2,292,375			3,692,832
Deferred tax liabilities:
Property and Equipment	—			(21,755		)
Definite-lived intangible assets	(2,292,375		)	(3,671,077		)
Indefinite-lived intangibles	—			(9,575		)
Total deferred tax liabilities	(2,292,375		)	(3,702,407		)
Net deferred tax liabilities	$	—		$	(9,575	)

Summary of Income Tax Contingencies

A reconciliation of the beginning and ending amounts of gross unrecognized tax benefits (excluding interest and penalties) is as follows:



	2015		2014
Beginning of fiscal year	$	—	$	121,000
Additions for tax positions of prior years	—		—
Reductions for tax positions of prior years	—		—
Reductions attributable to lapse of statute of limitations	—		(121,000		)
End of fiscal year	$	—	$	—

Stock Based Compensation (Tables)

12 Months Ended

Jan. 31, 2016

Employee Stock Ownership Plan (ESOP), Shares in ESOP [Abstract]

Schedule of Stock Option Activity

A summary of stock option activity follows:



	Options		Weighted Average Exercise Price			Remaining Life in Years	Aggregate intrinsic value
Outstanding as of February 1, 2015	2,437,323		$	4.52
Granted	1,011,828		3.02
Exercised	(75,000	)	2.15
Expired	(704,326	)	3.67
Forfeited	(257,946	)	4.97
Outstanding as of January 31, 2016	2,411,879		$	4.16	(1)	8.09	$	4,003,719
Exercisable as of January 31, 2016	1,000,037		$	4.75	(2)	6.82	$	1,660,061
Vested or expected to vest as of January 31, 2016	1,990,872		$	4.25		7.90	$	3,304,848

_______________


(1)	The exercise prices range from $1.53 to $8.17, of which 207,924 shares are between $1.53 and $2.00 per share, 862,938 shares are between $2.08 and $4.00 per share, and 1,341,017 shares are between $4.02 and $8.17 per share.


(2)	The exercise prices range from $1.53 to $8.17, of which 97,924 shares are between $1.53 and $2.00 per share, 268,356 shares are between $2.08 and $4.00 per share, and 633,757 shares are between $4.02 and $8.17 per share.

Schedule of Weighted-Average Assumptions

The fiscal 2015 and 2014 stock-based compensation was estimated at the date of grant using a Black-Scholes option pricing model with the following weighted average assumptions for each fiscal year:



	2015		2014
Expected life	6 years		6 years
Risk-free interest rate	1.51	%	1.35	%
Weighted average volatility factor	0.59		0.60
Dividend yield	—		—
Forfeiture rate	30	%	22	%

Schedule of Restricted Stock Award Activity

A summary of restricted stock award activity for fiscal 2014 and 2015 is presented below:



	Non-vested Number of Shares		Weighted Average Grant Date Fair Value
Non-vested balance at January 31, 2014	29,698		$	6.01
Granted	120,306		4.31
Vested	(29,698	)	6.65
Forfeited/expired	—		—
Non-vested balance at January 31, 2015	120,306		$	4.31
Granted	118,180		2.62
Vested	(120,306	)	4.31
Forfeited/expired	(5,800	)	4.31
Non-vested balance at January 31, 2016	112,380		$	2.62

Private Placement Investment (Tables)

12 Months Ended

Jan. 31, 2016

Equity [Abstract]

Schedule of Investment Allocation

The proceeds were allocated among the instruments based on their relative fair values as follows:



	Adjusted Fair Value at August 16, 2012		Proceeds Allocation at August 16, 2012
Instruments:
Series A Preferred Stock	$	9,907,820	$	6,546,146	(1)
Convertible subordinated notes payable	5,699,577		3,765,738		(2)
Warrants	2,856,000		1,688,116		(3)
Total investment	$	18,463,397	$	12,000,000

_______________

(1)

(2)

(3)

Series A Preferred Stock Activity

The following table sets forth the activity of the Series A Preferred Stock, classified as temporary equity, during the periods presented:



	Number of Shares	Series A Preferred Stock
Series A Preferred Stock, January 31, 2014	2,949,995	$	5,599,668
Accretion of Preferred Stock discount	—	1,038,310
Series A Preferred Stock, January 31, 2015	2,949,995	6,637,978
Accretion of Preferred Stock discount	—	1,336,072
Series A Preferred Stock, January 31, 2016	2,949,995	$	7,974,050

Schedule of Warrants Issued and Outstanding

The following table sets forth the warrants issued and outstanding as of January 31, 2016:



	Number of Shares Issuable	Weighted Average Exercise Price
Warrants - private placement	1,200,000	$	3.99
Warrants - placement agent	200,000	4.06
Total	1,400,000	$	4.00

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Significant Accounting Policies - Additional Information (Details)				12 Months Ended
	Dec. 13, 2013 ft²	Aug. 16, 2012 ft²	Apr. 10, 2012 ft²	Jan. 31, 2016 USD ($) segment shares	Jan. 31, 2015 USD ($) shares	Feb. 03, 2014 USD ($)	Jan. 31, 2013 USD ($)
Allowance for Doubtful Accounts
Allowance for doubtful accounts				$ 155,407	$ 665,962
Concessions Accrual
Concessions Costs				54,000	58,000
Bad debt expense				124,235	440,771
Leases
Property and equipment, net				2,454,075	3,136,815
Accumulated depreciation and amortization				2,407,746	1,617,423
Capitalized Software Development Costs
Capitalized computer software, additions				$ 0	620,000
Useful life of capitalized computer software				5 years
Capitalized computer software, amortization				$ 3,073,479	3,677,991
Research and development expense				9,093,353	9,756,206
Revenue Recognition
Deferred professional costs				571,000	570,000
Accumulated amortization, deferred finance costs				265,000	275,000
Amortization of professional expenses				$ 136,000	166,000
Goodwill and Intangible Assets
Number of operating segments \| segment				1
Number of reportable segments \| segment				1
Severances
Severance expenses				$ 43,000	666,000
Equity Awards
Share-based compensation expense				2,386,490	1,934,298
Comprehensive Loss
Other comprehensive income (loss)				0	111,086
Income Taxes
Reserves for uncertain tax positions and corresponding interest and penalties				$ 0	$ 0
Convertible Preferred Stock
Net Earnings (Loss) Per Common Share
Antidilutive securities \| shares				2,949,995	2,949,995
Restricted Stock
Net Earnings (Loss) Per Common Share
Antidilutive securities \| shares				112,380	120,306
Warrant
Net Earnings (Loss) Per Common Share
Antidilutive securities \| shares				1,400,000	1,400,000
Employee Severance
Severances
Accrued severances				$ 26,000	$ 159,000
Minimum
Goodwill and Intangible Assets
Estimated useful life				1 year
Maximum
Goodwill and Intangible Assets
Estimated useful life				15 years
Interpoint Partners, LLC
Leases
Area under lease (sq. ft.) \| ft²	24,335		8,582
Lease duration	102 months		72 months
Duration of rent allowance	8 months		4 months
Meta
Leases
Area under lease (sq. ft.) \| ft²		10,350
Lease duration		2 months
Duration of rent allowance		63 months
Assets Held under Capital Leases
Leases
Property and equipment, net				$ 1,652,000	1,515,000
Accumulated depreciation and amortization				$ 1,166,000	$ 494,000
Restricted Stock Award
Equity Awards
Required service period				1 year
Stock Options
Net Earnings (Loss) Per Common Share
Options outstanding \| shares				2,411,879	2,437,323
Internally-developed software \| Meta
Capitalized Software Development Costs
Intangible assets							$ 3,646,000
Internally-developed software \| Unibased
Capitalized Software Development Costs
Intangible assets					$ 2,017,000	$ 2,017,000

Significant Accounting Policies - Property, Plant, and Equipment (Details) - USD ($)	12 Months Ended
	Jan. 31, 2016	Jan. 31, 2015
Property, Plant and Equipment
Depreciation expense	$ 1,245,400	$ 1,005,283
Computer Equipment and Software \| Minimum
Property, Plant and Equipment
Property, plant and equipment, useful life	3 years
Computer Equipment and Software \| Maximum
Property, Plant and Equipment
Property, plant and equipment, useful life	4 years
Office Equipment
Property, Plant and Equipment
Property, plant and equipment, useful life	5 years
Office Furniture and Fixtures
Property, Plant and Equipment
Property, plant and equipment, useful life	7 years

Significant Accounting Policies - Capitalized Software Development Costs (Details) - USD ($)	12 Months Ended
	Jan. 31, 2016	Jan. 31, 2015
Accounting Policies [Abstract]
Cost of systems sales	$ 2,747,000	$ 3,352,000
Cost of software as a service	326,000	326,000
Total amortization expense on internally developed software	$ 3,073,479	$ 3,677,991

Significant Accounting Policies Significant Accounting Policies - Fair Value of Liabilities (Details) - USD ($) $ in Thousands	Jan. 31, 2016	Jan. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Royalty liability	$ 2,292	$ 2,386
Quoted Prices in Active Markets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Royalty liability	0	0
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Royalty liability	0	0
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Royalty liability	2,292	2,386
Warrant
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants liability	205	1,834
Warrant \| Quoted Prices in Active Markets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants liability	0	0
Warrant \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants liability	0	0
Warrant \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants liability	$ 205	$ 1,834

Significant Accounting Policies - Earnings Per Share (Details) - USD ($)	12 Months Ended
	Jan. 31, 2016	Jan. 31, 2015
Accounting Policies [Abstract]
Net loss	$ (4,290,115)	$ (12,011,457)
Less: deemed dividends on Series A Preferred Shares	(1,336,072)	(1,038,310)
Net loss attributable to common shareholders	$ (5,626,187)	$ (13,049,767)
Basic and diluted weighted average shares outstanding (shares)	18,689,854	18,261,800
Stock options and restricted stock	0	0
Number of average shares used in diluted per common share computation	18,689,854	18,261,800
Basic net loss per common share (in dollars per share)	$ (0.30)	$ (0.71)
Diluted net loss per common share (in dollars per share)	$ (0.30)	$ (0.71)

Acquisitions - Narrative (Details) - USD ($)			12 Months Ended
Acquisitions - Narrative (Details) - USD ($)	Feb. 03, 2014	Oct. 25, 2013	Jan. 31, 2016	Jan. 31, 2015
Business Acquisition [Line Items]
Cash paid			$ 0	$ 6,058,225
Royalty liability			$ 2,291,888	$ 2,385,826
Montefiore Medical Center
Business Acquisition [Line Items]
Proprietary lease term		15 years
Cash paid		$ 3,000,000
Periodic royalty payment term		6 years 6 months
Ongoing royalty payments		$ 3,000,000
Unibased
Business Acquisition [Line Items]
Cash paid	$ 6,118,000
Total purchase price	6,500,000
Proceeds received from escrow	$ 750,000

Acquisitions - Assets Acquired and Liabilities Assumed (Details) - USD ($)		12 Months Ended
	Feb. 03, 2014	Jan. 31, 2016	Jan. 31, 2015	Jan. 31, 2014
Assets purchased:
Goodwill		$ 16,184,667	$ 16,184,667	$ 11,934,000
Liabilities assumed:
Cash paid		$ 0	6,058,225
Unibased
Assets purchased:
Cash	$ 59,000
Accounts receivable	221,000
Other assets	61,000
Goodwill	4,251,000
Total assets purchased	7,282,000
Liabilities assumed:
Accounts payable and accrued liabilities	362,000
Deferred revenue obligation, net	793,000
Deferred income taxes	9,000
Net assets acquired	6,118,000
Cash paid	6,118,000
Client relationships \| Unibased
Assets purchased:
Intangible assets	647,000
Internally-developed software \| Unibased
Assets purchased:
Intangible assets	2,017,000		$ 2,017,000
Trade name \| Unibased
Assets purchased:
Intangible assets	$ 26,000

Derivative Liabilities (Details) - USD ($)		1 Months Ended	12 Months Ended
Derivative Liabilities (Details) - USD ($)	Oct. 19, 2012	Aug. 31, 2012	Jan. 31, 2016	Jan. 31, 2015	Oct. 31, 2012	Aug. 16, 2012
Derivative [Line Items]
Warrants exercisable (in shares) (up to)						1,200,000
Exercise price (USD per share)						$ 3.99
Net of transaction costs, allocated to the warrants		$ 1,425,000
Warrants liability			$ 205,113	$ 1,834,380
Valuation adjustment for warrants liability			$ 1,629,267	2,283,345
Annual volatility			60.10%
Risk-free rate			0.60%
Dividend yield			0.00%
Expected life			2 years
Annual volatility			55.00%
Risk-free rate			0.80%
Dividend yield			$ 0.000
Expected life			3 years
Estimate of Fair Value
Derivative [Line Items]
Warrants liability			$ 205,000	1,834,000
Common Stock Warrant
Derivative [Line Items]
Warrants exercisable (in shares) (up to)			1,400,000
Exercise price (USD per share)			$ 4.00
Common Stock Warrant \| Estimate of Fair Value
Derivative [Line Items]
Warrant liability at fair value			$ 205,000	$ 1,834,000
Placement Agent \| Common Stock Warrant
Derivative [Line Items]
Warrants exercisable (in shares) (up to)	200,000
Exercise price (USD per share)	$ 4.06
Annual volatility	75.00%
Risk-free rate	0.90%
Expected life	5 years
Placement Agent \| Common Stock Warrant \| Estimate of Fair Value
Derivative [Line Items]
Warrant liability at fair value					$ 4,139,000

Operating Leases (Details) - USD ($) $ in Thousands	12 Months Ended
Operating Leases (Details) - USD ($) $ in Thousands	Jan. 31, 2016	Jan. 31, 2015
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2016	$ 971
2017	1,007
2018	1,039
2019	967
2020	504
Thereafter	964
Total	5,452
Rent and leasing expense	1,274	$ 1,652
Facilities
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2016	969
2017	1,007
2018	1,039
2019	967
2020	504
Thereafter	964
Total	5,450
Equipment
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2016	2
2017	0
2018	0
2019	0
2020	0
Thereafter	0
Total	$ 2

Debt - Term Loan and Line of Credit Narrative (Details) - USD ($)			1 Months Ended	12 Months Ended
	Apr. 15, 2015	Nov. 21, 2014	Dec. 31, 2013	Jan. 31, 2016	Feb. 03, 2014
Debt Instrument [Line Items]
Revolving line of credit			$ 5,000,000
Subordinated Debt
Debt Instrument [Line Items]
Accrues interest rate			6.42%
Senior Notes
Debt Instrument [Line Items]
Senior term loan			$ 8,500,000
Installment payments due			$ 101,000
Borrowing under the revolving loan bears interest at a rate equal to LIBOR plus			5.25%
Closing fee			$ 116,000
Revolving Credit Facility
Debt Instrument [Line Items]
Commitment fee in connection with the term loan				$ 2,000
Borrowing under the revolving loan bears interest at a rate equal to LIBOR plus			3.50%
Commitment fee percentage			0.40%
Credit Agreement
Debt Instrument [Line Items]
Repayment of credit facility		$ 7,400,000
Debt discount					$ 315,000
Amortization of financing costs		355,000
Credit Agreement \| Senior term loan
Debt Instrument [Line Items]
Revolving line of credit		10,000,000
Credit Agreement \| Revolving Credit Facility
Debt Instrument [Line Items]
Revolving line of credit		$ 5,000,000
Minimum \| LIBOR \| Credit Agreement
Debt Instrument [Line Items]
Borrowing under the revolving loan bears interest at a rate equal to LIBOR plus	4.25%	4.25%
Minimum \| Base Rate \| Credit Agreement
Debt Instrument [Line Items]
Borrowing under the revolving loan bears interest at a rate equal to LIBOR plus	3.25%	3.25%
Maximum \| LIBOR \| Credit Agreement
Debt Instrument [Line Items]
Borrowing under the revolving loan bears interest at a rate equal to LIBOR plus	6.25%	5.25%
Maximum \| Base Rate \| Credit Agreement
Debt Instrument [Line Items]
Borrowing under the revolving loan bears interest at a rate equal to LIBOR plus	5.25%	4.25%
April 15, 2015 \| Credit Agreement
Debt Instrument [Line Items]
Minimum liquidity				5,000,000
April 16, 2015 through and including July 30, 2015 \| Credit Agreement
Debt Instrument [Line Items]
Minimum liquidity				6,500,000
July 31, 2015 through and including January 30, 2016 \| Credit Agreement
Debt Instrument [Line Items]
Minimum liquidity				7,000,000
January 31, 2016 through and including the maturity date \| Credit Agreement
Debt Instrument [Line Items]
Minimum liquidity				$ 7,500,000

Debt - Minimum EBITDA Levels (Details) - Credit Agreement	12 Months Ended
	Jan. 31, 2016 USD ($)
April 30, 2015
Debt Instrument [Line Items]
Minimum EBITDA level	$ (2,500,000)
July 31, 2015
Debt Instrument [Line Items]
Minimum EBITDA level	(1,750,000)
October 31, 2015
Debt Instrument [Line Items]
Minimum EBITDA level	(750,000)
January 31, 2016
Debt Instrument [Line Items]
Minimum EBITDA level	$ 500,000

Debt - Note Payable Narrative (Details) - USD ($)	1 Months Ended	12 Months Ended
Debt - Note Payable Narrative (Details) - USD ($)	Nov. 30, 2013	Jan. 31, 2016	Jan. 31, 2015	Dec. 31, 2013
Debt Instrument [Line Items]
Repayments of debt		$ 1,465,109	$ 8,297,620
Subordinated Debt
Debt Instrument [Line Items]
Accrues interest rate				6.42%
Subordinated Debt \| Unsecured Subordinated Notes Due November, 2016
Debt Instrument [Line Items]
Debt term	3 years
Convertible Note	$ 900,000
Accrues interest rate	8.00%
Principal payments	$ 300,000
Repayments of debt	$ 600,000

Debt - Summary of Term Loan and Line of Credit (Details) - USD ($) $ in Thousands	Jan. 31, 2016	Jan. 31, 2015
Debt Instrument [Line Items]
Total	$ 9,221	$ 11,365
Less: Current portion	1,266	1,282
Non-current portion of long-term debt	7,955	10,083
Senior Notes
Debt Instrument [Line Items]
Senior term loan	8,535	10,000
Capital Lease Obligations
Debt Instrument [Line Items]
Capital lease	$ 686	$ 1,365

Debt - Schedule of Future Principal Repayments of Long-Term Debt (Details) $ in Thousands	Jan. 31, 2016 USD ($)
Debt Instrument [Line Items]
Capital Leases, Payments Due by 2016	$ 618
Total Payments Due by 2016	1,292
Capital Leases, Payments Due by 2017	93
Total Payments Due by 2017	991
Capital Leases, Payments Due by 2018	0
Total Payments Due by 2018	898
Capital Leases, Payments Due by 2019	0
Total Payments Due by 2019	6,064
Capital Lease	711
Total	9,245
Senior Notes
Debt Instrument [Line Items]
Debt Payments Due by 2016	674
Debt Payments Due by 2017	898
Debt Payments Due by 2018	898
Payments Due by 2019	6,064
Long-term Debt	$ 8,534

Debt - Interest Rate Swap Narrative (Details) - Interest Rate Swap	Jan. 31, 2016 USD ($)	Jan. 31, 2014 effective_hedging_relationship interest_rate_derivative
Derivative [Line Items]
Number of effective hedging relationships \| effective_hedging_relationship		1
Number of interest rate swaps \| interest_rate_derivative		1
Fixed interest rate	6.42%
Notional amount	$ 8,500,000
Derivative liability	$ 111,000

Goodwill and Intangible Assets - Schedule of Goodwill Activity (Details)	12 Months Ended
	Jan. 31, 2015 USD ($)
Goodwill [Roll Forward]
Goodwill, beginning of period	$ 11,934,000
Goodwill acquired during fiscal 2014	4,251,000
Goodwill, end of period	$ 16,184,667

Goodwill and Intangible Assets - Schedule of Intangibles (Details) - USD ($)	12 Months Ended
	Jan. 31, 2016	Jan. 31, 2015
Intangible Assets, Net (Including Goodwill) [Abstract]
Gross Assets	$ 12,827,000	$ 12,827,000
Accumulated Amortization	4,672,000	3,327,000
Net Assets	8,155,000	9,500,000
Loss on impairment of intangible assets	$ 0	$ 1,952,000
Maximum
Intangible Assets, Net (Including Goodwill) [Abstract]
Estimated Useful Life	15 years
Minimum
Intangible Assets, Net (Including Goodwill) [Abstract]
Estimated Useful Life	1 year
Trade name
Intangible Assets, Net (Including Goodwill) [Abstract]
Estimated Useful Life	1 year	1 year
Gross Assets	$ 26,000	$ 26,000
Accumulated Amortization	26,000	26,000
Net Assets	0	0
Client relationships
Intangible Assets, Net (Including Goodwill) [Abstract]
Gross Assets	5,932,000	5,932,000
Accumulated Amortization	2,220,000	1,548,000
Net Assets	$ 3,712,000	$ 4,384,000
Client relationships \| Maximum
Intangible Assets, Net (Including Goodwill) [Abstract]
Estimated Useful Life	15 years	15 years
Client relationships \| Minimum
Intangible Assets, Net (Including Goodwill) [Abstract]
Estimated Useful Life	10 years	10 years
Covenants not to compete
Intangible Assets, Net (Including Goodwill) [Abstract]
Gross Assets	$ 856,000	$ 856,000
Accumulated Amortization	667,000	606,000
Net Assets	$ 189,000	$ 250,000
Covenants not to compete \| Maximum
Intangible Assets, Net (Including Goodwill) [Abstract]
Estimated Useful Life	15 years	15 years
Covenants not to compete \| Minimum
Intangible Assets, Net (Including Goodwill) [Abstract]
Estimated Useful Life	6 months	6 months
Supplier agreements
Intangible Assets, Net (Including Goodwill) [Abstract]
Estimated Useful Life	5 years	5 years
Gross Assets	$ 1,582,000	$ 1,582,000
Accumulated Amortization	1,094,000	778,000
Net Assets	$ 488,000	$ 804,000
License agreement
Intangible Assets, Net (Including Goodwill) [Abstract]
Estimated Useful Life	15 years	15 years
Gross Assets	$ 4,431,000	$ 4,431,000
Accumulated Amortization	665,000	369,000
Net Assets	$ 3,766,000	$ 4,062,000

Goodwill and Intangible Assets - Schedule of Future Amortization Expense (Details) - USD ($) $ in Thousands	Jan. 31, 2016	Jan. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
2016	$ 1,298
2017	1,088
2018	863
2019	826
2020	791
Thereafter	3,289
Net Assets	$ 8,155	$ 9,500

Income Taxes - Components of Income Tax Expense (Details) - USD ($)	12 Months Ended
	Jan. 31, 2016	Jan. 31, 2015
Current tax (expense) benefit:
Federal	$ 0	$ 131,816
State	(17,578)	34,611
Total current tax expense	(17,578)	166,427
Deferred tax benefit:
Federal	8,838	663,681
State	737	56,901
Total deferred tax benefit (expense)	9,575	720,582
Income tax (expense) benefit	$ (8,003)	$ 887,009

Income Taxes - Tax Provision at Statutory Rate Reconciliation (Details) - USD ($)	12 Months Ended
	Jan. 31, 2016	Jan. 31, 2015
Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]
Federal tax benefit at statutory rate	$ 1,455,816	$ 4,385,479
State and local taxes, net of federal benefit (expense)	(267,997)	325,966
Change in valuation allowance	(1,629,786)	(4,030,864)
Incentive stock options	(513,708)	(421,366)
Transaction costs	0	(5,291)
Escrow refund	255,000	0
Change in fair value of warrants liability	553,951	776,337
Other	(28,914)	(44,719)
Reserve for uncertain tax position	0	164,127
Other	167,635	(262,660)
Income tax (expense) benefit	$ (8,003)	$ 887,009

Income Taxes - Schedule of Deferred Tax Assets and Tax Carryforwards (Details) - USD ($)	Jan. 31, 2016	Jan. 31, 2015
Deferred tax assets:
Allowance for doubtful accounts	$ 58,379	$ 245,252
Deferred revenue	244,163	372,275
Accruals	203,291	174,658
Net operating loss carryforwards	15,179,685	14,905,174
Stock compensation expense	592,654	438,659
Property and equipment	78,295	0
AMT credit	102,144	102,144
Other	17,794	8,912
Total deferred tax assets	16,476,405	16,247,074
Valuation allowance	(14,184,030)	(12,554,242)
Net deferred tax assets	2,292,375	3,692,832
Deferred tax liabilities:
Property and Equipment	0	(21,755)
Definite-lived intangible assets	(2,292,375)	(3,671,077)
Indefinite-lived intangibles	0	(9,575)
Total deferred tax liabilities	(2,292,375)	(3,702,407)
Net deferred tax liabilities	$ 0	$ (9,575)

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Jan. 31, 2016	Jan. 31, 2015
Income Tax Contingency [Line Items]
Valuation allowance	$ 14,184,030	$ 12,554,242
Change in valuation allowance	1,629,786	$ 4,030,864
Unrecognized operating loss carryforwards for stock options	1,592,000
Unrecognized deferred tax asset for operating loss carryforwards for stock options	588,000
Internal Revenue Service (IRS)
Income Tax Contingency [Line Items]
Operating loss carryforwards	44,347,000
Change in valuation allowance	1,630,000
Internal Revenue Service (IRS) \| Alternative Minimum Tax
Income Tax Contingency [Line Items]
Operating loss carryforwards	39,656,000
State
Income Tax Contingency [Line Items]
Operating loss carryforwards, subject to expire next twenty fiscal years	$ 16,144,000

Income Taxes - Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2016	Jan. 31, 2015
Reconciliation of Unrecognized Tax Benefits [Roll Forward]
Beginning of fiscal year	$ 0	$ 121
Additions for tax positions of prior years	0	0
Reductions for tax positions of prior years	0	0
Reductions attributable to lapse of statute of limitations	0	(121)
End of fiscal year	$ 0	$ 0

Major Clients - (Details) - Customer Concentration Risk - customers	12 Months Ended
	Jan. 31, 2016	Jan. 31, 2015
Revenue
Concentration Risk
Concentration risk, number of customers	0	0
Accounts Receivable
Concentration Risk
Concentration risk, number of customers	2	2
Accounts Receivable \| Customer A
Concentration Risk
Concentration risk, percentage	13.00%	16.00%
Accounts Receivable \| Customer B
Concentration Risk
Concentration risk, percentage	12.00%	10.00%

Employee Retirement Plan (Details) - USD ($) $ in Thousands	12 Months Ended
Employee Retirement Plan (Details) - USD ($) $ in Thousands	Jan. 31, 2016	Jan. 31, 2015
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]
Matching contribution percent (up to)	100.00%
Maximum contribution as a percent of participant compensation	4.00%
Defined contribution plan, cost recognized	$ 499	$ 440

Employee Stock Purchase Plan Employee Stock Purchase Plan (Details) - USD ($) $ / shares in Units, $ in Thousands			12 Months Ended
	Jun. 30, 2016	Jan. 04, 2016	Jan. 31, 2016	Jan. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award
Shares remaining available for grant			528,164
Closing price		$ 1.41
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award
Number of shares authorized to be purchased under Employee Stock Purchase Plan			1,000,000
Employee Stock Purchase Plan, maximum annual contribution per employee, percent			10.00%
Employee Stock Purchase Plan, percent of fair market value, prior year			85.00%
Employee Stock Purchase Plan, percent of fair market value, current year			85.00%
Allocated share-based compensation expense			$ 20	$ 14
Cash received from purchase of shares under Employee Stock Purchase Plan			$ 115	$ 82
Employee Stock Purchase Plan \| $2.38 per share
Share-based Compensation Arrangement by Share-based Payment Award
Stock purchased during period, shares, Employee Stock Purchase Plan			27,071
Stock purchased during period, price per share, Employee Stock Purchase Plan			$ 2.38
Employee Stock Purchase Plan \| $1.20 per share
Share-based Compensation Arrangement by Share-based Payment Award
Stock purchased during period, shares, Employee Stock Purchase Plan			42,050
Stock purchased during period, price per share, Employee Stock Purchase Plan			$ 1.20
Employee Stock Purchase Plan \| $4.08 per share
Share-based Compensation Arrangement by Share-based Payment Award
Stock purchased during period, shares, Employee Stock Purchase Plan				11,141
Stock purchased during period, price per share, Employee Stock Purchase Plan				$ 4.08
Employee Stock Purchase Plan \| $3.68 per share
Share-based Compensation Arrangement by Share-based Payment Award
Stock purchased during period, shares, Employee Stock Purchase Plan				9,900
Stock purchased during period, price per share, Employee Stock Purchase Plan				$ 3.68
Scenario, Forecast [Member] \| Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award
Purchase price discount	85.00%

Stock Based Compensation - Additional Information (Details)		12 Months Ended
	Jan. 04, 2016 $ / shares	Jan. 31, 2016 USD ($) $ / shares shares	Jan. 31, 2015 USD ($) shares
Share-based Compensation Arrangement by Share-based Payment Award
Exercise price range, lower range limit (in USD per share) \| $ / shares	$ 1.41
Exercise price range, upper range limit (in USD per share) \| $ / shares		$ 8.17
Weighted average period of recognition for compensation cost		1 year 9 months 18 days
Proceeds from exercise of stock options and stock purchase plan \| $		$ 276,039	$ 551,583
Change in control percentage		0.2
$1.65 to $8.17
Share-based Compensation Arrangement by Share-based Payment Award
Exercise price range, lower range limit (in USD per share) \| $ / shares		$ 1.53
Exercise price range, upper range limit (in USD per share) \| $ / shares		$ 8.17
$1.65 to $2.00
Share-based Compensation Arrangement by Share-based Payment Award
Options outstanding		207,924
Exercise price range, lower range limit (in USD per share) \| $ / shares		$ 1.53
Exercise price range, upper range limit (in USD per share) \| $ / shares		$ 2.00
Options exercisable		97,924
$2.08 to $4.00
Share-based Compensation Arrangement by Share-based Payment Award
Options outstanding		862,938
Exercise price range, lower range limit (in USD per share) \| $ / shares		$ 2.08
Exercise price range, upper range limit (in USD per share) \| $ / shares		$ 4.00
Options exercisable		268,356
$4.08 to $8.17
Share-based Compensation Arrangement by Share-based Payment Award
Options outstanding		1,341,017
Exercise price range, lower range limit (in USD per share) \| $ / shares		$ 4.02
Options exercisable		633,757
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award
Options outstanding		2,411,879	2,437,323
Options issued		1,011,828
Options expired		704,326
Options forfeited		257,946
Options exercised		75,000
Options exercisable		1,000,037
Compensation cost not yet recognized \| $		$ 1,588,000
Allocated share-based compensation expense \| $		1,783,000	$ 1,655,000
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award
Allocated share-based compensation expense \| $		582,000	$ 265,000
Compensation cost not yet recognized \| $		$ 77,000
2013 Incentive Compensation Plan \| Blended Equity Awards (Stock Options, Stock Appreciation Rights, Resticted Stock)
Share-based Compensation Arrangement by Share-based Payment Award
Equity awards authorized (up to)		4,500,000
Term of options granted (or less)		10 years
Vesting period		3 years
Options outstanding		2,186,879	1,737,323
2013 Incentive Compensation Plan \| Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period		1 year
Executive Inducement Grants \| Stock Options
Share-based Compensation Arrangement by Share-based Payment Award
Options outstanding		225,000	700,000
Options issued		0	300,000
Options expired		405,417	125,694
Options forfeited		69,583	99,722
Options exercised		0	205,556

Stock Based Compensation - Summary of Stock Option Activity (Details) - Stock Options - USD ($)	12 Months Ended
	Jan. 31, 2016	Jan. 31, 2015
Stock Option Activity
Options, Outstanding - beginning of year	2,437,323
Options, Granted	1,011,828
Options, Exercised	(75,000)
Options, Expired	(704,326)
Options, Forfeited	(257,946)
Options, Outstanding - end of year	2,411,879	2,437,323
Options exercisable	1,000,037
Options, vested or expected to vest - end of year	1,990,872
Weighted Average Exercise Price Activity
Weighted Average Exercise Price, Outstanding - beginning of year (USD per share)	$ 4.52
Weighted Average Exercise Price, Granted (USD per share)	3.02
Weighted Average Exercise Price, Exercised (USD per share)	2.15
Weighted Average Exercise Price, Expired (USD per share)	3.67
Weighted Average Exercise Price, Forfeited (USD per share)	4.97
Weighted Average Exercise Price, Outstanding - end of year (USD per share)	4.16	$ 4.52
Weighted Average Exercise Price, Exercisable - end of year (USD per share)	4.75
Weighted Average Exercise Price, Vested or expected to vest - end of year (USD per share)	$ 4.25
Remaining Life in Years, Outstanding	8 years 1 month 2 days
Remaining Life in Years, Exercisable	6 years 9 months 26 days
Remaining Life in Years, Vested or expected to vest	7 years 10 months 25 days
Aggregate intrinsic value of outstanding options at year end	$ 4,003,719
Aggregate intrinsic value of exercisable options at year end	1,660,061
Aggregate intrinsic value of options vested or expected to vest at year end	$ 3,304,848
Weighted average grant date fair value of options granted during year (USD per share)	$ 1.64	$ 2.90
Total intrinsic value of options exercised during the year	$ 125,000	$ 990,000

Stock Based Compensation - Weighted Average Assumptions (Details) - USD ($)	12 Months Ended
	Jan. 31, 2016	Jan. 31, 2015
Employee Stock Ownership Plan (ESOP), Shares in ESOP [Abstract]
Expected life	6 years	6 years
Risk-free interest rate	1.51%	1.35%
Weighted average volatility factor	59.00%	60.00%
Dividend yield	$ 0	$ 0
Forfeiture rate	30.00%	22.00%

Stock Based Compensation - Schedule of Restricted Stock Award Activity (Details) - Restricted Stock - $ / shares	12 Months Ended
	Jan. 31, 2016	Jan. 31, 2015
Restricted Stock Award Activity
Non-vested number of shares, beginning of period	120,306	29,698
Shares granted	118,180	120,306
Shares vested	(120,306)	(29,698)
Shares forfeited/expired	(5,800)	0
Non-vested number of shares, end of period	112,380	120,306
Weighted Average Fair Value Activity
Weighted average grant date fair vale, at beginning of period (USD per share)	$ 4.31	$ 6.01
Weighted average grant date fair value, granted (USD per share)	2.62	4.31
Weighted average grant date fair value, vested (USD per share)	4.31	6.65
Weighted average grant date fair value, forfeited/expired (USD per share)	4.31	0.00
Weighted average grant date fair vale, at end of period (USD per share)	$ 2.62	$ 4.31

Private Placement Investment - Additional Information (Details) - USD ($)	Nov. 01, 2012	Aug. 16, 2012	Jan. 31, 2016	Jan. 31, 2015
Class of Stock [Line Items]
Warrants exercisable (in shares)		1,200,000
Exercise price (USD per share)		$ 3.99
Placement and other advisor fees		$ 1,894,000
Cost of warrants issued		754,000
Deferred finance costs		611,000	$ 270,147	$ 387,199
Issuance of common stock warrants		263,000
Common Stock Warrant
Class of Stock [Line Items]
Warrants exercisable (in shares)			1,400,000
Exercise price (USD per share)			$ 4.00
Private Placement
Class of Stock [Line Items]
Proceeds allocation		$ 12,000,000
Common shares issued for convertible note and accrued interest (in shares)	1,583,210	1,583,210
Private Placement \| Series A Preferred Stock
Class of Stock [Line Items]
Proceeds allocation		$ 6,546,146
Issuance of common stock		2,416,785
Preferred stock dividend rate (as a percent)		0.00%
Share price (USD per share)		$ 3.00	$ 8.00
Preferred stock, discount on shares		$ 1,020,000	$ 4,410,000
Private Placement \| Common Stock Warrant
Class of Stock [Line Items]
Proceeds allocation		$ 1,688,116
Warrants exercisable (in shares)		1,200,000
Exercise price (USD per share)		$ 3.99
Private Placement \| Convertible Subordinated Notes Payable
Class of Stock [Line Items]
Proceeds allocation		$ 3,765,738
Convertible notes payable	$ 5,699,577	$ 5,699,577

Private Placement Investment - Schedule of Investment Allocation (Details) - USD ($)			12 Months Ended
	Nov. 01, 2012	Aug. 16, 2012	Jan. 31, 2016
Instruments:
Annual volatility			55.00%
Risk-free rate			0.80%
Expected life			3 years
Private Placement
Instruments:
Total investment, Fair Value		$ 18,463,397
Proceeds allocation		12,000,000
Private Placement \| Common Stock Warrant
Instruments:
Warrants, Fair Value		2,856,000
Proceeds allocation		$ 1,688,116
Annual volatility		75.00%
Risk-free rate		0.90%
Dividend yield		0.00%
Expected life		5 years
Private Placement \| Convertible Subordinated Notes Payable
Instruments:
Convertible subordinated notes payable, Fair Value		$ 5,699,577
Proceeds allocation		3,765,738
Private Placement \| Series A Preferred Stock
Instruments:
Series A Preferred Stock, Fair Value		9,907,820
Proceeds allocation		$ 6,546,146
Conversion basis		1
Maximum conversion period	4 years	4 years
Stock price at time of conversion (USD per share)			$ 3.00
Annual volatility		75.00%
Risk-free rate		0.90%
Dividend yield		0.00%
Private Placement \| Minimum \| Series A Preferred Stock
Instruments:
Stock price at time of conversion (USD per share)		$ 3.00
Private Placement \| Maximum \| Series A Preferred Stock
Instruments:
Stock price at time of conversion (USD per share)		$ 8.00

Private Placement Investment - Series A Convertible Preferred Stock Narrative (Details) - USD ($)			12 Months Ended
	Nov. 01, 2012	Aug. 16, 2012	Jan. 31, 2016	Jan. 31, 2015	Jan. 31, 2014
Class of Stock [Line Items]
Period over which share price is evaluated			10 days
Accretion of preferred stock discount			$ 0	$ (47,552)
Annual volatility			55.00%
Risk-free rate			0.80%
Redemption price per share (USD per share)			$ 3.00
Common stock
Class of Stock [Line Items]
Common stock, market value per share (USD per share)		$ 3.82
Series A Preferred Stock
Class of Stock [Line Items]
Accretion of preferred stock discount			$ 1,336,072
Convertible redeemable preferred stock, shares outstanding			2,949,995	2,949,995	2,949,995
Shares converted					1,050,000
Amount converted					$ (3,150,000)
Convertible Notes to Preferred Stock \| Series A Preferred Stock
Class of Stock [Line Items]
Preferred stock, par value (USD per share)	$ 5.80
Conversion basis	1
Loss upon conversion	$ 5,913,000
Issuance of shares at redemption value for conversion of notes payable	9,183,000
Carrying value and unamortized deferred financing costs	3,270,000
Difference between fair value and redemption value recorded as additional paid in capital	$ 4,433,000
Annual volatility	75.00%
Risk-free rate	0.80%
Dividend yield	0.00%
Private Placement
Class of Stock [Line Items]
Common shares issued for convertible note and accrued interest (in shares)	1,583,210	1,583,210
Private Placement \| Series A Preferred Stock
Class of Stock [Line Items]
New issuance of series A convertible preferred stock		2,416,785
Preferred stock, par value (USD per share)		$ 3.00
Conversion basis		1
Share price (USD per share)		$ 3.00	$ 8.00
Period over which trade volume is evaluated			60 days
Average daily trading volume for period (in shares)			100,000
Stock price at time of conversion (USD per share)			$ 3.00
Preferred stock, discount on shares		$ 1,020,000	$ 4,410,000
Beneficial conversion feature			2,686,000
Accretion of preferred stock discount			$ 1,336,000	$ (1,038,310)
Annual volatility		75.00%
Risk-free rate		0.90%
Dividend yield		0.00%
Maximum conversion period	4 years	4 years
Private Placement \| Convertible Subordinated Notes Payable
Class of Stock [Line Items]
Convertible notes payable	$ 5,699,577	$ 5,699,577
Private Placement \| Convertible Notes to Preferred Stock \| Series A Preferred Stock
Class of Stock [Line Items]
Aggregate redemption value	$ 4,750,000
Minimum \| Convertible Notes to Preferred Stock \| Series A Preferred Stock
Class of Stock [Line Items]
Stock price at time of conversion (USD per share)	$ 3.00
Minimum \| Private Placement \| Series A Preferred Stock
Class of Stock [Line Items]
Stock price at time of conversion (USD per share)		$ 3.00
Maximum \| Convertible Notes to Preferred Stock \| Series A Preferred Stock
Class of Stock [Line Items]
Stock price at time of conversion (USD per share)	$ 8.00
Maximum \| Private Placement \| Series A Preferred Stock
Class of Stock [Line Items]
Stock price at time of conversion (USD per share)		$ 8.00

Private Placement Investment - Schedule of Series A Preferred Stock Activity (Details) - USD ($)	12 Months Ended
	Jan. 31, 2016	Jan. 31, 2015
Increase (Decrease) in Temporary Equity [Roll Forward]
Accretion of Preferred Stock discount	$ 0	$ (47,552)
Series A Preferred Stock
Increase (Decrease) in Shares of Temporaty Equity [Roll Forward]
Beginning Balance (in shares)	2,949,995	2,949,995
Period End Balance (in shares)	2,949,995	2,949,995
Increase (Decrease) in Temporary Equity [Roll Forward]
Beginning balance	$ 6,637,978	$ 5,599,668
Accretion of Preferred Stock discount	1,336,072
Period end balance	7,974,050	6,637,978
Private Placement \| Series A Preferred Stock
Increase (Decrease) in Temporary Equity [Roll Forward]
Accretion of Preferred Stock discount	$ 1,336,000	$ (1,038,310)

Private Placement Investment - Common Stock Warrants Narrative (Details) - USD ($)			1 Months Ended	12 Months Ended
	Oct. 19, 2012	Aug. 16, 2012	Aug. 31, 2012	Jan. 31, 2016	Jan. 31, 2015	Oct. 31, 2012
Class of Stock [Line Items]
Warrants exercisable (in shares)		1,200,000
Weighted average exercise price (USD per share)		$ 3.99
Net of transaction costs, allocated to the warrants			$ 1,425,000
Annual volatility				55.00%
Risk-free rate				0.80%
Expected life				3 years
Common Stock Warrant
Class of Stock [Line Items]
Warrants exercisable (in shares)				1,400,000
Weighted average exercise price (USD per share)				$ 4.00
Private Placement \| Common Stock Warrant
Class of Stock [Line Items]
Warrants exercisable (in shares)		1,200,000
Weighted average exercise price (USD per share)		$ 3.99
Net of transaction costs, allocated to the warrants		$ 1,425,000
Fair value of warrants		$ 2,856,000
Annual volatility		75.00%
Risk-free rate		0.90%
Dividend yield		0.00%
Expected life		5 years
Placement Agent \| Common Stock Warrant
Class of Stock [Line Items]
Warrants exercisable (in shares)	200,000
Weighted average exercise price (USD per share)	$ 4.06
Fair value of warrants	$ 754,000
Annual volatility	75.00%
Risk-free rate	0.90%
Dividend yield	0.00%
Expected life	5 years
Estimate of Fair Value \| Common Stock Warrant
Class of Stock [Line Items]
Derivative liability				$ 205,000	$ 1,834,000
Estimate of Fair Value \| Placement Agent \| Common Stock Warrant
Class of Stock [Line Items]
Derivative liability						$ 4,139,000

Private Placement Investment - Schedule of Warrants Issued and Outstanding (Details) - $ / shares	Jan. 31, 2016	Aug. 16, 2012
Share-based Compensation Arrangement by Share-based Payment Award
Number of shares issuable (in shares)		1,200,000
Weighted average exercise price (USD per share)		$ 3.99
Common Stock Warrant
Share-based Compensation Arrangement by Share-based Payment Award
Number of shares issuable (in shares)	1,400,000
Weighted average exercise price (USD per share)	$ 4.00
Placement Agent \| Common Stock Warrant
Share-based Compensation Arrangement by Share-based Payment Award
Number of shares issuable (in shares)	200,000
Weighted average exercise price (USD per share)	$ 4.06
Private Placement \| Common Stock Warrant
Share-based Compensation Arrangement by Share-based Payment Award
Number of shares issuable (in shares)	1,200,000
Weighted average exercise price (USD per share)	$ 3.99

Schedule II - Valuation and Qualifying Accounts and Reserves (Details) - USD ($)	12 Months Ended
	Jan. 31, 2016	Jan. 31, 2015
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	$ 665,962
Charged to Costs and Expenses	1,629,267	$ 2,283,345
Balance at End of Period	155,407	665,962
Allowance for doubtful accounts
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	666,000	267,000
Charged to Costs and Expenses	48,000	441,000
Charged to Other Accounts	0	1,000
Deductions	(559,000)	(43,000)
Balance at End of Period	$ 155,000	$ 666,000

Major Clients	12 Months Ended
Major Clients	Jan. 31, 2016
Segment Reporting [Abstract]
MAJOR CLIENTS	MAJOR CLIENTS During fiscal year 2015, no individual client accounted for 10% or more of our total revenues. Two clients represented 13% and 12%, respectively, of total accounts receivable as of January 31, 2016. During fiscal year 2014, no individual client accounted for 10% or more of our total revenues. Two clients represented 16% and 10%, respectively, of total accounts receivable as of January 31, 2015.

Subsequent Events	12 Months Ended
Subsequent Events	Jan. 31, 2016
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS We have evaluated subsequent events through April 20, 2016 and have determined that there are no subsequent events after January 31, 2016 for which disclosure is required.

Organization and Description of Business (Details)	12 Months Ended
Organization and Description of Business (Details)	Jan. 31, 2016 segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating segments	1